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ABSTRACT 
Mental health issues are medical problems getting increased attention 
throughout the world, and depression, only one among several types of 
mental illnesses, are currently reported as the second leading cause of 
disability world wide by the World Health Organization. Along this 
development, increased number of psychiatric diagnoses and increased 
utilization of medication can be observed. However, whether this increase is 
because of an actual increase in number of individuals suffering from these 
disorders, or due to improvements in diagnostics and understanding, or 
both, is not fully known. What is known, however, is that mental health 
related suffering is nothing new and can be traced back several thousands of 
years in human history. Throughout this history, our understanding and view 
of these disorders that affect our mood and behavior have changed 
substantially, from being assumed caused by gods or magic, to our modern 
view of combined environmental and genetic causes. But psychiatry is still a 
comparatively recent field of medicine and it was not long ago effective drugs 
targeting these disorders were first introduced. Our understanding of the 
underlying mechanisms of this suffering is still limited, but recent 
developments in psychiatric genetics have provided some of the first stable 
biological underpinnings to mental disorders. In light of these findings, a 
complicated picture is beginning to take form, in which the etiology appears 
caused by thousands of genetic factors, but also that a lot of the underlying 
genetics is shared among the disorders previously thought of as separate. 
It is within this setting, where many of the current disorder definitions are 
starting being questioned and the appreciation of genetics behind these 
disorder is increasing, the studies within thesis have been conducted.  
In study I, the potential side effect of manic switching due to antidepressant 
treatment was investigated in a population sample of 3,240 individuals with 
bipolar disorder. A within-individual design was used to adjust for otherwise 
unmeasured genetic confounding, and the results indicated that manic 
switching was confined to bipolar disorder patients treated with an 
antidepressant monotherapy, whereas patients treated with an 
antidepressant in combination with a mood stabilizer rather displayed a 
reduced risk. 
Study II instead focused on depression around the time of pregnancy, 
perinatal depression, and to what extent genetics explain the variance in this 
disorder, and to what extent perinatal depression genetically overlap with 
depression at other time of life. This was studied with a twin design in a 
sample of twin mothers (N=3,427) that had answered the Edinburgh 
Postnatal Depression Scale, and with a sibling design in a sample of sisters 
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(N=580,006) using register data of healthcare contacts. The genetic 
contribution to, or heritability of, perinatal depression was estimated at 54 
and 44% in the twin and sibling designs respectively. Using a bivariate 
model, a third of the genetic contribution to perinatal depression was found 
unique for the disorder and not shared with depression at other times of life. 
Study III was also related to perinatal depression, but focused on potential 
side effects of antidepressants. In a sample of 392,029 pregnancies, 
associations between prenatal SSRI exposure and offspring birth size and 
gestational age was observed. This was followed by within-family analyses 
(N=1,007) that adjusted for genetic and familial environmental confounding, 
where the associations between SSRIs and offspring birth size was 
attenuated, indicating that these associations were likely due to familial 
confounding. An association between prenatal SSRI exposure and reduced 
gestational age was observed in both analyses, and could be either due to a 
causal effect of the medication, or due to confounding factors that the within-
family design could not adjust for. 
Perinatal depression was further explored in study IV, where patterns of 
healthcare utilization were studied among both mothers and fathers based on 
register data. This included 3.6 million parents and 3.5 million pregnancies, 
and the occurrence of diagnoses for depressive illness, anxiety disorders, and 
mental illness in general around the time of pregnancy was contrasted to the 
occurrence of these diagnoses at other times of life. Overall, a reduction in 
healthcare utilization for all studied disorder types were observed around this 
time of life, which may indicate barriers to getting a diagnosis during this 
time of life. 
In conclusion, the studies within this thesis demonstrate that genetically 
informed designs are very useful in epidemiological research. And through 
the application of these designs with large-scale register data, the studies of 
this thesis provide enhanced understanding of mental illness in general, and 
bipolar disorder and perinatal depression in particular. 
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SAMMANFATTNING PÅ SVENSKA 
 
Psykisk ohälsa är ett medicinskt problem som får allt mer utrymme i vårt 
samhälle och i världen. Depression, som bara är en utav många olika 
psykiska sjukdomar, anses i dag av Världshälsoorganisationen WHO vara 
den näst största orsaken till funktionsnedsättning i hela världen. Med denna 
utveckling syns en ökning i antal psykiatriska diagnoser och användning av 
läkemedel. Men huruvida denna ökning beror på en ökning i antal sjuka, 
eller om det är en ökning som kan härledas till ökad förståelse och bättre 
diagnostik, eller båda delar, är i dag inte känt. Däremot är det känt att 
psykiskt lidande inte är något nytt, utan något som kan följas flera tusen år 
tillbaka i den mänskliga historien. Genom denna historia har vår förståelse 
och syn på dessa sjukdomar som påverkar humör och beteende förändrats 
avsevärt, från tron på inverkan av gudar och magi, till dagens moderna 
uppfattning att psykisk ohälsa beror på miljö och arv i samspel. Men 
psykiatrin är fortfarande ett relativt ungt område inom medicinen, och det 
var inte länge sedan det inte fanns några specifika läkemedel mot psykiskt 
lidande. Vår förståelse kring de underliggande mekanismerna bakom 
psykiska sjukdomar är fortfarande mycket begränsade, men den senaste 
tidens utveckling inom den psykiatriska genetiken har försett forskare med 
de första solida kopplingarna mellan psykiskt lidande och biologi. I ljuset av 
dessa fynd har en komplicerad bild börjat ta form, där tusentals genetiska 
faktorer verkar ligga till grund för dessa sjukdomar, och där flertalet psykiska 
sjukdomar som tidigare ansetts vara skilda nu förefaller ha delad genetik. 
Det är i denna kontext, där många av dagens definitioner av psykiska 
sjukdomar börjat ifrågasättas och där insikterna kring genetikens betydelse 
för dessa sjukdomar ökar, som studierna i denna avhandling har genomförts. 
I studie I undersöktes den potentiella bieffekten "manisk switch" -  d.v.s. en 
plötslig övergång från depression till mani eller hypomani - på grund utav 
antidepressiv medicinering i en grupp bestående utav 3240 individer som 
lider av bipolär sjukdom. En inom-individs-analys applicerades för att kunna 
kontrollera för effekter som beror på individens specifika genetik, och 
resultaten pekade på att manisk switch var begränsad till de individer med 
bipolär sjukdom som behandlats med antidepressiv medicinering enbart. 
Bland individer med bipolär sjukdom som även erhållit 
stämningsstabiliserande medicin observerades istället en minskad risk. 
Studie II fokuserade istället på depression kring tiden för graviditet, också 
kallad perinatal depression, och i vilken utsträckning genetik förklarar 
orsaken till denna sjukdom, och i vilken utsträckning perinatal depression 
överlappar genetiskt med depression under annan tid i livet. Detta 
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studerades i en tvillingstudie bestående utav 3 427 tvillingmödrar genom 
svar som lämnats på formuläret Edinburgh Postnatal Depression Scale, samt 
i en syskonstudie bestående utav 580 006 systrar där registerdata på 
sjukhusbesök istället användes. Ärftligheten, det vill säga i vilken 
utsträckning genetik bidrar, av perinatal depression estimerades till 54 
respektive 44% i tvilling- och syskonstudien var för sig. Dessutom 
uppskattades en tredjedel av genetiken bakom perinatal depression vara unik 
för denna sjukdom, och delades inte med depression under annan tid av 
livet. 
Studie III var också relaterad till perinatal depression, men fokuserade på 
potentiella bieffekter av antidepressiv medicinering. I en studie av 392 029 
graviditeter observerades först associationer mellan prenatal SSRI-
medicinering och födelsestorlek samt gestationsålder. Detta följdes av en 
inom-familjs-analys (N=1 007) som kontrollerade för arv och miljö delat 
mellan två helsyskon. Denna analys fann inte några associationer mellan 
SSRI och födelsestorlek, vilket tyder på att denna koppling troligtvis berodde 
på underliggande arv eller miljö, och inte på medicineringen. Däremot 
observerades en association mellan prenatal SSRI-exponering och lägre 
gestationsålder i båda analyserna, vilket kan bero på en kausal effekt av 
SSRI-medicineringen, eller på grund utav andra underliggande faktorer som 
inom-familjsanalysen inte kunde kontrollera för. 
Perinatal depression studerades vidare i studie IV, där mönster i 
sjukvårdsnyttjande studerades hos 3,6 miljoner föräldrar och 3,5 miljoner 
graviditeter. Förekomsten av depressions-, ångest-, samt generella psykiska 
diagnoser estimerades under tiden kring graviditet och jämfördes med 
kringliggande perioder. Överlag observerades en minskning av 
sjukvårdsanvändande för alla studerade sjukdomstyper, vilket kan innebära 
att det finns hinder för att få en psykiatrisk diagnos under denna tid i livet. 
Sammanfattningsvis ger denna avhandling stöd för att studier som utnyttjar 
genetisk information är mycket användbara i epidemiologisk forskning. 
Genom applicering av dessa metoder tillsammans med storskalig 
registerdata ger studierna i denna avhandling ökad förståelse kring psykiska 
sjukdomar i allmänhet, och kring bipolär sjukdom och perinatal depression i 
synnerhet. 
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1.1 BACKGROUND 
Whereas the field of psychiatry is a relatively young medical specialty, its 
focus, mental illness, is nothing new and it is said that Hippocrates, born in 
460 BC in ancient Greece, coined the term melancholia.1-3 However, the 
ancient Greeks were not the only culture at the time to distinguish mood 
disorders and the distress and impairment it entails. Similar states of mood 
were described in India approximately a hundred years before Hippocrates,4 
and continued to be described throughout history; among isolated Egyptian 
monks circa 350 AD, in medieval Europe, and into modern times.5 The cause 
of this suffering has been attributed to both magic and Gods,6 and is today 
generally believed to be due to a combination of environmental and genetic 
factors. However, in contrast to many somatic disorders, discerning the 
causal mechanisms behind mental illnesses has proven difficult, and our 
understanding of the underlying processes is still limited.7-9 
To better grasp these difficulties, it can be useful to contrast psychiatric 
disorders with somatic disorders. A somatic disorder such as leukemia - a 
cancer that affects the bone marrow or blood - can initially present with signs 
and symptoms including fatigue, fever, and bruises.10 The illness can further 
be diagnosed by blood and bone marrow tests that allow blood cells to be 
counted and the morphology of the cells studied, information that is used to 
classify the type of leukemia.10 Clinicians can additionally investigate how 
organs in the body are affected by the leukemia using an array of imaging 
techniques based on x-ray, magnetic resonance, computed tomography, or 
ultrasound.10 The cancerous cells can also be genotyped, allowing 
identification of certain mutations that are associated with better or worse 
outcome,11 or present targets for specific pharmacological treatment.11-13 
In comparison, the definition and detection of non-organic psychiatric 
disorders do not involve any underlying biology, and are instead based on 
descriptive symptoms related to the mood or behavior of the affected 
individual.14,15 This is, at least in part, because these disorders affect the 
brain, the most complicated and least understood component of the human 
body, which is protected from the rest of the circulation by a blood-brain 
barrier. This renders peripheral blood tests unsuitable for studying the blood 
composition inside the brain, and makes invasive tests potentially very 
dangerous. While there are numerous methods employed in psychiatric 
research, including brain imaging, biomarkers, and genetics, none of theses 
approaches have yet resulted in new ways to diagnose mental illnesses. 
Behavioral or mood symptomatology is still the golden standard in 
psychiatric diagnosis, which can prove problematic. This is because a 
psychiatric diagnosis is dependent on what information the patient provides, 
and what information a clinician is able to comprehend. And even if this 
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information exchange is perfect, the symptoms that can be identified are 
likely shared by many different underlying causes. A similar, although not 
perfect, example would be the somatic symptom of fever. Fever is useful to 
distinguish illness, and could even provide an indication of the type of illness. 
But by itself, this symptom is not very useful if we want to distinguish the 
exact underlying mechanism behind the illness. The fever could be due to a 
viral or bacterial infection, related to cancer, or an effect of an autoimmune 
disorder. In all of these disorders, a general anti-inflammatory treatment 
could decrease the fever symptoms, but to treat the underlying cause 
different approaches would need to be employed. In a similar way, an 
antidepressant medication may reduce the symptoms of depression, but the 
exact underlying mechanisms behind the depressive symptoms are not yet 
understood and there could be many different processes causing the mood 
symptoms defined as depression. 
Much research is focused on finding biological underpinnings to mental 
illness,7 and psychiatric genetics has so far been one of the most successful 
approaches.8,9,16-24 Our genes are stable over life and can be assessed 
quantitatively by modeling familial structures, or direct by genotyping of 
DNA from peripheral cells. However, the extent of understanding of mental 
illness provided by genetic research is still limited and has not yet produced 
new means of clinical diagnosis. Nevertheless, the research into psychiatric 
genetics has provided new insights into the underlying structure of mental 
illness, indicating shared genetic determinants between many, if not all, 
mental disorders,8,22,25 and potential heterogeneity in depressive illness.9 
This etiological heterogeneity and genetic overlap suggest that our current 
disorder definitions are not as distinct as previously thought,26 and may 
partially explain the difficulties in finding a suitable medication for many 
patients. While there are general guidelines for the pharmacological 
treatment of specific psychiatric disorders with a first line of treatment,27 the 
reality is often that the individual response can be very varied and include 
everything from a good response, to a low response requiring higher dosing, 
to non-response.28,29 On top of that there are side effects that also vary 
between individuals, including for example extrapyramidal side effects, 
weight gain, and the potentially lethal side effect Stevens-Johnson 
Syndrome.30-32 
 
1.2 DEPRESSION 
Depressive illness is mainly diagnosed either based on the criteria presented 
in the Diagnostic and Statistical Manual of Mental Disorders (DSM),14 
provided by the American Psychiatric Association, or based on the criteria 
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presented in the International Statistical Classification of Diseases and 
Related Health Problems (ICD),15 provided by the World Health 
Organization. The most recent version of the DSM is the DSM-5 that was 
introduced in 2013, whereas the most recent version if the ICD is the ICD-10 
introduced in 1992, with the 11th version of the ICD planned for 2017. 
Although the nomenclature differs between the DSM and ICD, with the DSM 
using major depressive episode to denote a single episode of depression, and 
major depressive disorder to denote a recurrent or chronic illness, and the 
ICD instead using depressive episode and recurrent depressive disorder, 
both systems defines depressive illness as distinct and persistent depressed 
mood accompanied with somatic and cognitive signs and symptoms, and the 
criteria used by the DSM and ICD display similar abilities to identify 
depression.33,34 In Sweden, both somatic and psychiatric illness is diagnosed 
according to the ICD system,35 and the 2015 version of the ICD-10 uses the 
code F32 for a depressive episode and provides the following definition: 
"In typical mild, moderate, or severe depressive episodes, the patient suffers 
from lowering of mood, reduction of energy, and decrease in activity. 
Capacity for enjoyment, interest, and concentration is reduced, and marked 
tiredness after even minimum effort is common. Sleep is usually disturbed 
and appetite diminished. Self-esteem and self-confidence are almost always 
reduced and, even in the mild form, some ideas of guilt or worthlessness are 
often present. The lowered mood varies little from day to day, is 
unresponsive to circumstances and may be accompanied by so-called 
"somatic" symptoms, such as loss of interest and pleasurable feelings, 
waking in the morning several hours before the usual time, depression 
worst in the morning, marked psychomotor retardation, agitation, loss of 
appetite, weight loss, and loss of libido. Depending upon the number and 
severity of the symptoms, a depressive episode may be specified as mild, 
moderate or severe." 
Depression is a common illness with a one-year prevalence estimated at 5-
7%,36,37 and is a devastating disorder that is associated with substantial 
morbidity and mortality,38-40 and can include suicide.41 In 1996, using data 
from 1990, The World Health Organization reported depressive illness as the 
fourth leading cause of disability world wide,42 while also projecting 
depressive illness to become the second leading cause of disability by 
2020.43,44 In 2004, using data from 2000, the World Health Organization 
reported that depressive illness was now the third leading cause of 
disability.45 When the data from 2010 was reported in 2013, depressive 
illness had become the second leading cause of disability, ten years earlier the 
predictions made in 1996.46 The extent of the disability caused by depressive 
illness further entails a large economic impact on the society. The cost of 
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depression in Europe, in 2005 alone, has been estimated at 120 billion 
euro,47 or approximately 1,110 billion Swedish kronor. Studies of Swedish 
patients have estimated the cost of depression at 17,000 euro per patient and 
year.48-50  
The criteria used to classify depression are broad,14,15 and the specified 
symptoms are similar to symptoms displayed by an individual who 
experience "understandable" intense sadness. Heritability studies of 
depression have estimated the genetic contribution at around 37%,51,52 which 
is considerably lower than for bipolar disorder or schizophrenia at around 
70%.22,53,54 This implies that, quantitatively, environmental factors play a 
dominant role in the development of depression. Further, whereas multi-
national large-scale genome wide association studies of schizophrenia and 
bipolar disorder have successfully identified several risk loci,16-19,55 similar 
efforts with major depressive disorder have so far failed to distinguish any 
robust findings.9 The low estimated heritability and lack of findings from 
genome-wide association studies have been suggested to indicate that 
depression is a heterogeneous disorder,9 and that the current definition may 
cover subtypes of depression that by themselves may have a higher 
heritability.51,56,57 
1.2.1 DEPRESSION AROUND THE TIME OF PREGNANCY 
The prevalence of depression during the perinatal period, that is either 
during pregnancy or within a 3 to 12 month postpartum period, has been 
estimated at around 10-15% among women.58-61 This is a high figure 
considering the limited time the perinatal period(s) make up in most 
women's life and can, like depression in general, present with considerable 
morbidity, mortality, and costs both for the suffering individual and the 
society,58,59,62-65 But whereas depression as a whole has been extensively 
studied, depressive illness specifically around the time of pregnancy and 
childbirth has been conspicuously understudied.66,67 This is manifested by 
the numerous designations and definitions used in the literature to describe 
depressive illness during this specific time of life, and the lack of a good 
distinction. Both the DSM and ICD include postpartum depression as a 
separate category of depression,14,15 which has made this term the most well 
recognized one. However, both the DSM-IV and ICD-10 classify postpartum 
depression as depressive illness with an onset during the puerperium, that is, 
within four to six weeks after delivery. This is potentially a quite narrow 
definition considering research have shown that the risk of a psychiatric 
hospital admission is elevated through 3 months following childbirth,68,69 
and through 5 months for depression in particular.69 Research has further 
shown that depression with an antenatal onset, i.e. during pregnancy, is 
almost as common as postnatal onset depression.70,71 With the release of the 
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fifth edition of the DSM, the definition of postpartum depression saw an 
expansion by including antenatal onset. However, while this modification is 
important as it acknowledge the pregnancy as a risk period for developing 
depression, it also risk generating further confusion by including the 
antenatal time period under a name that specifically implies the time period 
after childbirth. Another term with increasing use in the literature is 
perinatal depression.58,64,72-79 The perinatal period includes both the 
pregnancy (antepartum, or the antenatal period) and a period after childbirth 
(postpartum, or the postnatal period). However, neither the DSM, nor the 
ICD, recognizes this term, and the length of the postpartum period included 
in the perinatal definition varies among studies.58 
To complicate matters further, there are large discrepancies between 
prevalence estimates of perinatal depression depending on the identification 
method used, with estimates based on healthcare utilization generally only 
being a fraction (0.5-1.6%)73,80,81 of the estimates based on self-report 
instruments like the Edinburgh Postnatal Depression Scale (10-15%).58-60 
This opens up for different potential explanations; either the self-report 
instruments overestimate the problem, or a lot of depression around the time 
of pregnancy is not being treated. Anxiety disorders, beside depressive 
illness, has been shown to constitute a substantial problem in the postpartum 
period.82,83 Studies have further shown that the Edinburgh Postnatal 
Depression Scale is detecting, but not distinguishing, anxiety,83-86 which 
could potentially explain the higher prevalence of perinatal depression 
estimated using the Edinburgh Postnatal Depression Scale. However, studies 
have also revealed a number of barriers to healthcare seeking among 
pregnant or new mothers, including insufficient understanding of pregnancy 
related mental issues, acceptance of exaggerated or false information, and 
concerns of stigma around mental illness.87,88 It has been shown that few 
pregnant women fulfilling the criteria for major depressive disorder receive 
treatment,89,90 and that treatment received is not adequate.91 Moreover, 
studies show that some women oppose further healthcare interaction after an 
initial screening,92 and there is an increased discontinuation in 
antidepressant use and depression care visits during pregnancy.93 It is 
therefor likely that the figures based on hospital treatment underestimate the 
size of the problem. 
Moreover, besides being a potentially undertreated cause of distress and 
impairment during a very vulnerable time of life, perinatal depression has 
been suggested being a subtype of depression with partially distinct 
biological underpinnings. Pregnancy and childbirth includes major 
fluctuations of numerous endogenous substances including, among others, 
reproductive hormones, oxytocin, cortisol, and prolactin.94 It has been 
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hypothesized that abnormal changes in any of these substances may 
contribute to the development of perinatal depression, but so far results have 
been inconclusive.94-96 
 
1.3 BIPOLAR DISORDER 
In contrast to unipolar depression, bipolar disorder, as implied by the name, 
present with both periods of depressed mood and periods of elevated mood, 
as well as euthymic (normal) mood, and mixed mood states including both 
depressed and manic symptoms.14 The elevated mood can further be 
categorized into either mania, a state of elevated mood that includes 
psychotic symptoms, or hypomania if the elevated mood lacks psychotic 
symptoms.14,97 In the presence of mania, the bipolar spectrum disorder is 
defined as bipolar I disorder, whilst in the presence of hypomania and in the 
absence of mania, the bipolar spectrum disorder is defined as bipolar II 
disorder.14,97 The prevalence of bipolar spectrum disorders has been 
estimated at 2.4%,98 and it is the sixth-leading cause of disability according to 
the World Health Organization.99 Due to the numerous potential 
manifestations of the disorder, many which are present in other psychiatric 
disorders, misdiagnosis is not uncommon.100-103 Without knowledge of a 
patient's medical history, a treating physician could interpret a manic 
episode as schizophrenia, or an episode of bipolar depression as unipolar 
depression. This is further complicated as bipolar disorder is dominated by 
depression,97 with episodes of depression being three times more common 
than episodes of elevated mood.104-106  
 
1.4 PHARMACOLOGICAL TREATMENT OF PSYCHIATRIC 
DISORDERS 
The introduction of the typical anti-psychotic drug chlorpromazine in the 
beginning of the 1950s was a fundamental event in the beginning of the 
modern pharmacological treatment of psychiatric disorders.107,108 While 
amphetamines and opioids had been used for some conditions prior the 
1950s, their effectiveness in more severe psychiatric conditions were limited, 
and the addictive properties was problematic.109,110 A large number of drugs 
targeting mental illness was introduced following chlorpromazine, and the 
pharmacological treatments reshaped psychiatry and drastically reduced, or 
replaced, the use of therapies including insulin chock therapy, 
psychosurgery, and hydrotherapy, and was followed by a large reduction in 
psychiatric inpatient care.107,111 
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1.4.1 PHARMACOLOGICAL TREATMENT OF DEPRESSION 
The modern day antidepressants emerged in the late 1950s with the 
introduction of the first tri-cyclic antidepressant imipramine, which was 
initially researched in an attempt to develop a more effective version of 
chlorpromazine.112-114 Although the term "antidepressant" is well known 
today, at the time of their introduction, many of these newly discovered drugs 
targeted against depressive mood was rather described with other names, e.g. 
thymoleptic (imipramine),115 or psychic energizer (iproniazid).116 Following 
the tri-cyclic antidepressants came the selective serotonin re-uptake 
inhibitors (SSRI) that are selective for the serotonergic signaling system of 
the brain, as opposed to the tricyclic compounds that affect a wide variety of 
signaling pathways.117 Fluoxetine, first described in 1974,118 was the first 
major SSRI drug and was sold under the brand name Prozac. In comparison 
to the tri-cyclic antidepressants, the selective serotonin re-uptake inhibitors 
have fewer side effects and are safer for the patients, which also make them 
more tolerable.31,119 A number of other antidepressant drugs have been 
introduced after the SSRIs, including the selective serotonin-norepinephrine 
re-uptake inhibitors (SNRI),120 and bupropion.121 The medication with 
antidepressants have seen a large increase over the last decades, with SSRIs 
making up the largest increase and constitute the most common 
antidepressant prescribed today.122-126 
1.4.2 PHARMACOLOGICAL TREATMENT OF DEPRESSION DURING 
PREGNANCY 
Pharmacological treatment of pregnant women is complicated by several 
factors. In 1957, the German pharmaceutical company Chemie Grünenthal 
introduced the sedative drug thalidomide that targeted anxiety, insomnia, an 
nausea.127 The drug was sold under the name Contergan in Germany, and 
under the name Neurosedyn in Sweden, and was seen as particularly suitable 
for pregnant women because of the profile of the effects.127,128 However, the 
use of thalidomide led to an international catastrophe due to the extreme 
side effects of teratogenic deformities in children prenatally exposed to the 
drug. It has been estimated that over 10,000 children was exposed during the 
few years the drug was marketed, of which a large portion did not 
survive.127,128Although the thalidomide catastrophe resulted in new stricter 
laws and directions to protect patients and offspring, it also led the American 
Food and Drug Administration (FDA) to expand the already existing ban on 
drug testing in pregnant women to include all "women of childbearing 
potential",129 effectively making most women ineligible to participate in 
clinical trials of new drugs.129 
Another complicating factor is the inability to use randomized controlled 
trials. In other groups, randomized controlled trials can be employed to test 
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the effects of a drug versus a placebo treatment. Studies on prenatal 
medication exposure instead have to be based on observational data. In this 
naturalistic setting, where all exposed women have been prescribed a 
medication due to a specific indication, the treated and non treated 
individuals will most likely be different in more aspects than the medication 
per se. For example, having or not having the disorder that led to the 
medication, which in turn can be affected by a certain genetic makeup or 
certain environmental exposures. It is possible that a factor underlying the 
medication fully or partially explains an observed association between a drug 
and an outcome. See the following sections 1.5, 1.6, and 1.7 for details about 
confounding, randomized controlled trials, and pharmacoepidemiology. 
Today, antidepressant medication during pregnancy is not uncommon, and 
the prescriptions of SSRIs have increased among pregnant women just like it 
has increased in the general population.130-132 But the use is not without 
controversy as there have been reports of many potential side effects. Studies 
of mice have reported smaller head size of mice prenatally exposed to 
SSRIs,133 and abnormal wiring of the somatosensory cortex and the lateral 
geniculate nucleus in the brain in serotonin transporter knockout mice.134 
Studies of humans have shown that antidepressants pass the placenta,135 and 
a large number of observational studies have reported associations between 
prenatal SSRI exposure and numerous adverse outcomes, including preterm 
birth,136-138 persistent pulmonary hypertension,139,140 septal heart defects,141 
lower birth weight,138,142 lower gestational age,136,142 malformations at 
birth,143,144  fetal death,138 reduced fetal head growth,145 autism,146,147 and 
anxiety.148 However, with use of observational studies only, it is difficult to 
disentangle whether these associations are due to the drug per se, or due to 
other factors correlating with the medication.  
1.4.3 PHARMACOLOGICAL TREATMENT OF BIPOLAR DISORDER 
Pharmacological treatment of bipolar disorder is complex. The illness 
present with both elevated and depressed mood, which are generally targeted 
by different drugs. Mania or hypomania is effectively attenuated with mood 
stabilizers (lithium, valproic acid, and carbamazepine) or atypical anti-
psychotics (quetiapine, lurasidone, and olanzapine).149-151 However, except 
for quetiapine and olanzapine, these drugs have limited efficacy in treating 
bipolar depression. And even though the atypical antipsychotics quetiapine 
and olanzapine may be effective in attenuating both elevated and depressed 
mood, their numerous side effects make them less favorable as a long-term 
treatment option.32 Instead antidepressants are usually prescribed to treat 
bipolar depression, and with depression being the most common abnormal 
mood state in bipolar disorder,106 it is not surprising that antidepressants 
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constitute half of all psychotropic medication prescribed to patients suffering 
from this illness.152 
But antidepressant treatment in bipolar disorder is also a controversial topic. 
Firstly, whereas evidence for the efficacy of antidepressants in treating 
unipolar depression is well documented,153 this is not the case for bipolar 
depression and some advocate not using antidepressant drugs at all in 
bipolar disorder.154,155 Secondly, already after the introduction of the first 
antidepressant imipramine in the 1950s, clinicians noted that some patients 
seemed to switch into a manic or hypomanic state following treatment 
initiation.113,114 This treatment emergent mania has since been extensively 
studied,156-165 and current guidelines caution against the use of 
antidepressant drugs in bipolar disorder because it is believed that such 
treatment increases the risk of a manic episode.27,166 Guidelines further 
suggest adding a mood-stabilizer medication in conjunction to the 
antidepressant treatment if antidepressants have to be used, but whether 
mood-stabilizers protect against antidepressant induced switch has only 
previously been explored by a handful studies.158,167-171 
 
1.5 CAUSAL INFERENCE AND CONFOUNDING 
In epidemiological research, participants are studied in an observational 
setting. This means that exposures are not assigned randomly by a 
researcher, but rather follow an underlying non-random naturalistic pattern. 
An observational study may find an association between the exposure X and 
the outcome Y, but the association may not be causal. Instead, another factor, 
U, may underlie both the exposure and the outcome and is then known as a 
confounder. A somewhat silly example could be an association between ice-
cream consumption and drowning accidents that in turn likely is confounded 
by warm weather that increases the chances of both ice-cream consumption 
and swimming and thereby drowning. 
Other examples of confounding that are exceedingly difficult to adjust for in a 
standard approach are underlying genetics or previous environmental factors 
that are complicated to measure. An example is an association between 
hormone replacement therapy in women and several health benefits,172 that 
in turn was shown confounded by an active and health conscious lifestyle - it 
turns out that women who pursued a healthy lifestyle also pursued the 
treatment that initially was believed to benefit health, but in reality increased 
the risk of for example breast cancer.173,174 This example is important, as it 
highlights the problems with confounding in general, and the problems with 
adjusting for potential confounding factors in particular. Most, if not all, 
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epidemiological studies adjust for measured confounding factors. However, 
not all confounding factors will be known, leaving a lot of unmeasured 
confounders unadjusted for. Research has further shown that genes influence 
behavior and mood and that this is likely done through variation in 
thousands of genes,8,9,16,20,21,175-177 It is therefor likely that the observational 
studies in the example with hormone replacement therapy were confounded 
by unmeasured genetics or unmeasured individual specific environment that 
could influence the health interest and thus affect both the willingness to use 
the medication perceived as healthy, and the outcomes related to better 
health.  
A way to handle confounding from complex underlying factors could be by 
using a within-individual design that contrasts the studied outcome in a 
period of non-exposure, with a period of exposure, for example medication, 
in the same individual. This approach consequently adjusts for underlying 
unmeasured confounding like genetics. It also adjusts for any environmental 
factors the individual has been exposed to up until the start of follow up. 
However, this design has limitations. It may be difficult to adjust for factors 
that may change over time during the follow up, consequently making studies 
of long-term exposure and outcomes that are known to increase or decrease 
over time complicated. In the example of the hormone replacement therapy, 
it may prove difficult to discern causes from a therapy used over several 
years, as this exposure have to be contrasted to an equally long untreated 
period. Over these years, the individual inevitably grows older, which may 
affect the studied outcomes. 
Another approach could be a family or sibling design, an approach that 
utilize the relatedness between siblings or family members and contrast an 
outcome in an exposed sibling to an unexposed sibling.178 Full siblings share 
on average 50% of their segregating alleles, with the absolute majority 
sharing between 40-60%.179 The design will therefor on average adjust for 
half of the underlying genetics, while offering the possibility to study an 
exposure that can only occur once, for example a prenatal exposure. 
However, this design also has limitations, including the inability to adjust for 
changes in behavior as a consequence of perceived consequences of exposure, 
and the potential of overestimating an association that is confounded by 
unshared environmental factors.180 See chapter 5.6 for more details about 
these limitations. 
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1.6 RANDOMIZED CONTROLLED TRIALS 
Results from adequately powered randomized controlled trials are commonly 
held as the most reliable scientific evidence and is referred to as the golden 
standard.149,181,182 In this setting, a group of individuals are first screened for 
eligibility to participate in the study and then randomly assigned to either a 
treatment or control group.183 Both groups are treated and followed in the 
same way, with the only difference being that the control group is not 
receiving the active compound or treatment being studied.183 A pronounced 
outcome observed exclusively in the treated group of an adequately sized and 
randomized study can be assumed caused by the treatment, as both groups 
are treated in the same way and other potential factors that could influence 
the outcome will be randomly scattered and can be assumed to affect the two 
groups equally, thereby reducing or eliminating influence from confounding 
factors. 
However, randomized controlled trials have limitations. Individuals prone to 
a side-effect may to a larger extent chose not to participate due to previous 
bad experiences of the studied treatment, consequently underestimating the 
potential side effects. On the other hand, more severely affected individuals 
may chose to join the study to a larger extent in hope of a new treatment, but 
may also be more susceptible to side-effects, consequently overestimating the 
side effects. Furthermore, this type of study takes a lot of time and involves a 
lot of people, consequently leading to very high costs.184,185 This reduces the 
extent of the study through for example focus on a single treatment, in a 
specific setting, and with strict eligibility criteria of the participants, thereby 
limiting the generalizability - or the external validity - of the results.186,187 
Individuals suffering from a mental illness are often treated with multiple 
drugs, and the narrow setting of a single study may question the results 
validity in other settings.187 Furthermore, the narrow eligibility criteria for 
participation often exclude individuals with a severe disorder, individuals 
with comorbidity, individuals with drug misuse problems, younger or elderly 
people, or women of childbearing age.186 None of these situations are 
uncommon, particularly not in psychiatry, so even though results from 
randomized controlled trials have high reliability, the result may be 
applicable only to a small portion of patients.187 
 
1.7 PHARMACOEPIDEMIOLOGY 
Pharmacoepidemiology is the study of drug effects, both intended and side 
effects, in an observational setting using survey data on drug use, or data 
from a drug prescription register.188 The latter commonly results in large-
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scale datasets that has a number of strengths in comparison to randomized 
controlled trials. First, the approach is usually much less costly than a 
randomized controlled trial. The data also includes a lot more individuals, 
and the data is collected in a naturalistic setting that includes groups that 
would not be surveyed in randomized controlled trials, like children, the 
elderly, severely affected patients, and pregnant women.188 The large scale 
also allows easier means of studying simultaneous medications, and can 
provide information on long-term treatment.189,190 The information may 
further be used to study patterns of medication prescription and medication 
dispensation.191,192 
However, by using observational data, pharmacoepidemiological studies are 
at the same risk of being confounded like normal epidemiological 
approaches. Moreover, by studying a particular treatment, 
pharmacoepidemiological studies may be affected by confounding by 
indication. That is, the indication that led to the medication might act as a 
confounder. This could for example be the case if the exposure is treatment 
with a mood stabilizing medication and the outcome is mania. If the rates of 
mania in mood stabilizer treated patients are contrasted to untreated 
patients, an increased level of mania will likely be observed among the 
treated patients. However, this will typically not reflect a mania inducing 
property of the mood stabilizing medication, but rather the underlying mania 
the medication was prescribed to treat. It will also likely reflect the fact that 
patients receiving a treatment in an observational setting are different from 
patients not receiving treatment, even though both patient groups have the 
same diagnosis. Another limitation of pharmacoepidemiological approaches 
is that the exact medication use is unknown, as there is no information on 
whether reported medication use, or prescribed and dispensed medication, 
was actually consumed. Instead, these studies have to rely on assumptions of 
medication use patterns.  
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 AIMS 2.
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The overarching objective of this thesis was to gain better understanding of 
the mood disorders bipolar disorder and depression, and consequences of 
pharmacological treatment, with a special focus on the perinatal period.  
Specifically, the aim of each study was as follows: 
Study I: To explore the potential mania inducing properties of 
antidepressants among individuals with bipolar disorder, either when used 
alone or when used together with a mood stabilizing medication. 
Study II: To estimate the heritability of perinatal depression and the 
heritability of non-perinatal depression, and to what extent these two 
definitions of depression overlap genetically. 
Study III:  To examine associations between maternal selective serotonin 
re-uptake inhibitor use during pregnancy and birth size related outcomes in 
the offspring. 
Study IV: To investigate the patterns of healthcare utilization for depression 
in and around the perinatal period. 
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 MATERIALS & METHODS 3.
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3.1 DATA SOURCES 
The studies within this thesis rely on observational data obtained from 
national Swedish registers. These registers are managed by Swedish 
government agencies, e.g. the National Board of Health and Welfare 
(Socialstyrelsen), and Statistics Sweden (Statistiska Centralbyrån), which 
work together with, and collect data from, healthcare providers, pharmacies, 
and the Swedish Tax Agency (Skatteverket), among others. Although these 
national registers can be very comprehensive on their own, linking them 
together vastly expands the number of exposures and outcomes that can be 
investigated. A precise linkage can be facilitated through the use of the 
unique Swedish personal identification number that is provided at birth, or 
at immigration to the country.193 On request by researchers, and after 
approval by an ethics board, and approval by the government agency, or 
agencies, responsible for the registers, linking of the data can be made. 
However, this procedure is completed by the governing agencies and when 
the data from these registers are delivered to research institutions, the 
unique Swedish personal identification number has been decoded and 
replaced with a unique sequence number. 
Below follows descriptions of each register contributing data to the studies 
within this thesis. 
3.1.1 THE NATIONAL PATIENT REGISTER 
The Swedish National Patient Register (National Board of Health and 
Welfare) covers information on all admissions to inpatient hospital care since 
1973, and all admissions to outpatient specialists since 2001.35 The register, 
however, does not include information from the Swedish primary care. The 
register contains admission dates along with the main and secondary 
discharge diagnosis codes in accordance with the International Classification 
of Disease (ICD). In Sweden, every admission to hospital care, or healthcare 
provider visit, results in at least one diagnosis code. 
3.1.2 THE SWEDISH PRESCRIBED DRUG REGISTER 
The Swedish Prescribed Drug Register (National Board of Health and 
Welfare) holds information an all prescribed drugs that have been dispensed 
from a pharmacy in Sweden.194 The register was initiated in July 2005 and 
currently represents one of the more recently established nation-wide 
registers in Sweden. Every entry in the register has, among other variables, a 
prescription date along with a corresponding dispensation date, the product 
name of the medication and generic name of the drug together with dose and 
package size, and a medication code in accordance with the Anatomical 
Therapeutic Chemical Classification System (ATC). However, the register 
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does not contain information on prescriptions that has not been dispensed 
from the pharmacies.  
3.1.3 THE SWEDISH MEDICAL BIRTH REGISTER 
The Swedish Medical Birth Register (National Board of Health and Welfare) 
covers 99% of all births since 1973.195 The National Board of Health and 
Welfare collects data from antenatal care units, delivery units, and pediatric 
examinations of the newborn. Data from these different sources are 
combined into the register and every birth hold a large number of variables 
that are routinely reported by the health care professionals. These include, 
among many others, date of birth, gestational age, birth weight, birth length, 
birth head circumference, and parity. 
3.1.4 THE MULTI-GENERATION REGISTER 
The Swedish Multi-Generation Register (Statistics Sweden) contains 
information on first-degree relatives for persons born 1932 and later.196 As of 
2005, the register contained information on 9,371,000 index individuals, of 
which 82% were Swedish born. At this point, maternal information was 
available for 97% of the Swedish born, and for 27% of the individuals born 
outside Sweden. Paternal information was available for 95% of the Swedish 
born, and for 22% of the individuals born outside Sweden. 
3.1.5 THE CAUSE OF DEATH REGISTER 
The Cause of Death Register (National Board of Health and Welfare) was 
initiated 1961, is updated yearly, and provides information on all deaths 
among Swedish residents, including both Swedish citizens and non-citizens, 
and deaths occurring both in Sweden and outside Sweden. The register 
includes the date of death, and cause of death based on diagnosis codes 
according to the ICD system.197 
3.1.6 THE TOTAL POPULATION REGISTER 
The Total Population Register (Swedish tax Agency) contains information on 
place of birth, place of residence, marital status, and information on 
migration.198 
3.1.7 THE SWEDISH TWIN REGISTRY 
The Swedish Twin Registry (Karolinska Institutet) contains almost all 
Swedish twins born between 1886-1990, and is the largest population-based 
twin registry in the world 199,200 Information on twin births are provided by 
the National Board of Health and Welfare, and subsets of twins, or their 
parents, are approached by the Swedish Twin Registry and invited to 
participate in studies. 
   33 
The Screening Across the Lifespan Twin study: the Younger (SALTY) 
Twin data used in this thesis project mainly stems from the Screening Across 
the Lifespan Twin study: the Younger (SALTY). The SALTY study was 
conducted between 2009-2010 and included 11,372 twins from the Swedish 
Twin Registry with a median birth year of 1950 of whom 54.3% were 
female.201 The SALTY study included an extensive self-report questionnaire 
that covered many different areas, including perinatal depression through a 
retrospective version of the Edinburgh Postnatal Depression Scale 
(EPDS).58,76,202,203 
3.1.8 LONGITUDINAL INTEGRATION DATABASE FOR HEALTH INSURANCE 
AND LABOR MARKET STUDIES (LISA) 
The longitudinal integration database for health insurance and labor market 
studies (LISA, Statistics Sweden) contains information on all individuals 16 
years of age or above residing in Sweden.204 The database started in 1990, 
contains information on education, family income, marital status etc. and is 
updated the 31st of December each year. Due to being updated once per year, 
changes between theses dates will not be detected. 
3.1.9 SMALL AREA MARKETING STATISTICS (SAMS) REGISTER  
Small Area Marketing Statistics (SAMS) Register is a geographical 
classification system including around 9,200 residential areas in Sweden, 
provided by Statistics Sweden.205 
 
3.2 MEASURES 
3.2.1 BIPOLAR DISORDER 
The Swedish National Patient Register provides information on healthcare 
admissions with discharge codes for bipolar disorder according to the ICD 
system.35 Due to the complicated nature of bipolar disorder there is a risk of 
misclassification. However, a validation of the bipolar disorder diagnoses in 
the National Patient Register by Sellgren and colleagues have resulted in a 
search algorithm yielding a positive predictive value of 0.93.206 This 
algorithm requires at least two bipolar disorder diagnoses (ICD-8 296.00, 
296.01, 296.03, 296.88, and 296.99; or ICD-9 296.0, 296.1, 296.3, 296.4, 
296.8, and 296.9; or ICD-10 F30 and F31), or one diagnosis of bipolar 
disorder and one diagnosis of major depressive disorder (unipolar 
depression) according to ICD-8 296.20 or ICD-9 296.2. Further, this 
algorithm allows no more than one diagnosis of schizophrenia (ICD-8 295; or 
ICD-9 295; or ICD-10 F25). This algorithm was used for sensitivity analyses 
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in study II, while in study I, a modified version of this algorithm was used 
that 1) did not allow a diagnosis of unipolar depression to be counted towards 
the required two diagnoses, and 2) did not allow any diagnosis of 
schizophrenia. 
3.2.2 MANIA 
The outcome mania was specifically studied in study I, and was defined using 
hospital discharge diagnosis codes for mania. As the follow-up for study I was 
between 2005 and 2009 when ICD-9 was no longer used in Sweden, only 
ICD-10 codes were used (F30.0, F30.1, F30.2, F30.8, F30.9, F31.0, F31.1, and 
F31.2). 
3.2.3 UNIPOLAR DEPRESSION 
Similar to bipolar disorder, unipolar depression was defined using healthcare 
contacts in the National Patient Register with discharge code for unipolar 
depression (ICD-8 296.00, 296.40, 296.41, 790.20; ICD-9 296.2, 296.3, 
296.9, 298.0, 300.4, 309.0, 309.1, and 311; or ICD-10 F32.0, F32.1, F32.2, 
F32.3, F32.8, F32.9, F33.0, F33.1, F33.2, F33.3, F33.4, F33.8, F33.9, F34.1, 
and F41.2). At least one admission with a discharge diagnosis for unipolar 
depression was used to define depression. 
3.2.4 PERINATAL DEPRESSION 
Using register data 
Perinatal depression was defined as at least one admission with a discharge 
diagnosis for unipolar depression (defined above), within pregnancy or 
within a six-month postpartum period. Using the birthdate and gestational 
age provided in the Medical Birth Register, a conception date was calculated 
by subtracting the gestational age from the birthdate. The pregnancy period 
was then defined as the time between the conception date and the birthdate, 
allowing the pregnancy period to be dynamic and better represent the actual 
time the mother was pregnant. The six-month postpartum period was 
defined as the period making up the 183 days after childbirth. 
Using the Edinburgh Postnatal Depression Scale 
A lifetime version of the Edinburgh Postnatal Depression Scale was used to 
assess perinatal depression among the twin mothers in study II.76 The 
Edinburgh Postnatal Depression Scale is the most widely used self-report 
assessment instrument for depressive illness during pregnancy of after 
childbirth in the world and has demonstrated good sensitivity and specificity 
in both depression during pregnancy and after childbirth.58,202 The lifetime 
version of the Edinburgh Postnatal Depression Scale comprises the same ten 
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items used in the original instrument, see Figure 3.1 below, but is modified to 
assess previously experienced (or lifetime) perinatal depression.76 A score of 
twelve or above on the scale is the acknowledged standard cut-off and has 
been extensively used in the literature.202,203 Twin mothers neither reporting 
feeling depressed during the pregnancy, nor during the six-month 
postpartum period, were classified as non-depressed. The same applied to 
twin mothers reporting feeling depressed in either period, but getting a total 
score below 12 on the Edinburgh Postnatal Depression Scale, whereas twin 
mothers getting a score of 12 or above was classified as depressed. Reporting 
feeling depressed in either period but failing to complete every item of the 
Edinburgh Postnatal Depression Scale resulted in exclusion. 
 
Figure 3.1. The ten items of the original Edinburgh Postnatal Depression Scale. 
 
1. I have been able to laugh and see the funny 
side of things.  
☐ As much as I always could  
☐ Not quite so much now  
☐ Definitely not so much now  
☐ Not at all  
 
2. I have looked forward with enjoyment to 
things. 
☐ As much as I ever did  
☐ Rather less than I used to  
☐ Definitely less than I used to  
☐ Hardly at all  
 
3. I have blamed myself unnecessarily when 
things went wrong.  
☐ Yes, most of the time  
☐ Yes, some of the time  
☐ Not very often  
☐ No, never  
 
4. I have been anxious or worried for no good 
reason.  
☐ No, not at all  
☐ Hardly ever  
☐ Yes, sometimes  
☐ Yes, very often  
 
5. I have felt scared or panicky for not very 
good reason.  
☐ Yes, quite a lot  
☐ Yes, sometimes  
☐ No, not much  
☐ No, not at all  
6. Things have been getting on top of me.  
☐ Yes, most of the time I haven't been able to 
cope at all  
☐ Yes, sometimes I haven't been coping as well 
as usual  
☐ No, most of the time I have coped quite well  
☐ No, I have been coping as well as ever  
 
7. I have been so unhappy that I have had 
difficulty sleeping.  
☐ Yes, most of the time  
☐ Yes, sometimes  
☐ Not very often  
☐ No, not at all  
 
8. I have felt sad or miserable.  
☐ Yes, most of the time  
☐ Yes, quite often  
☐ Not very often  
☐ No, not at all  
 
9. I have been so unhappy that I have been crying. 
☐ Yes, most of the time  
☐ Yes, quite often  
☐ Only occasionally  
☐ No, never  
 
10. The thought of harming myself has occurred to 
me.  
☐ Yes, quite often  
☐ Sometimes  
☐ Hardly ever  
☐ Never    
 
Antenatal and postnatal depression 
At least one hospital admission with a discharge diagnosis for unipolar 
depression within the pregnancy was defined as antenatal depression. 
Postnatal depression was defined as at least one hospital admission with a 
discharge diagnosis for unipolar depression within a twelve-month 
postpartum period. The postpartum time-window was expanded, from the 
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six months used in the definition of perinatal depression, to twelve months to 
allow inclusion of enough cases to allow heritability estimation in study II. 
3.2.5 ANXIETY DISORDERS 
Anxiety disorders were defined as at least one healthcare contact with the 
primary care, outpatient specialists, or an admissions to inpatient care with a 
discharge diagnosis code for an anxiety disorder according to any of the 
following codes: ICD-8 300, except 300.4; ICD-9 300, except 300.9; or ICD-
10 F40, F41, F42, F44, F45, or F48. 
3.2.6 PHARMACOLOGICAL TREATMENT 
Medication prescriptions and dispensations were identified from the Swedish 
Prescribed Drug Register,194 using the drug ATC codes and the dispensation 
dates from the pharmacies. In study I, a single dispensation of an 
antidepressant drug was used to define antidepressant medication. In the 
same study, mood stabilizer use was defined as at least two dispensations of 
lithium, valproic acid, or lamotrigine, over a certain period. See chapter 4.1 
for details. In study III, medication with an SSRI was defined as at least two 
dispensations of an SSRI drug during pregnancy, or around the time of 
pregnancy. See chapter 4.3 for details. Therefor, the definition of 
antidepressant medication was different between study I, that only required 
one dispensation, and study III that required at least two dispensations. 
Reasons and implications of this difference is discussed in more detail in 
chapter 5.2  
3.2.7 OFFSPRING BIRTH OUTCOMES 
The birth data on gestational age in days, birth length in centimeters, birth 
weight in grams, and birth head circumference in centimeters, were all 
obtained from the Medical Birth Register. Preterm birth is defined as 
childbirth within the first 37 weeks of gestation,207 and this cutoff was used to 
further dichotomize gestational age into preterm birth. 
A deviation in gestational age will naturally affect any of the birth size 
variables, as a child born earlier has had less time to develop before birth. To 
handle this, the birth size outcomes were standardized by gestational age by 
using the mean and standard deviation among children born within the same 
gestational week. The resulting standardized birth size outcomes do therefor 
not represent the exact value, but rather the deviation from the normal at a 
specific gestational week. 
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3.3 QUANTITATIVE GENETICS 
The classical twin model 
The classical twin model can be used to estimate the heritability of a trait and 
rely on the differing genetic within pair similarity between monozygotic twins 
and dizygotic twins. Monozygotic - or identical twins - share all of their 
genes, whereas dizygotic twins share on average half of their segregating 
genes. In other words, dizygotic twins, just like other siblings, may be more 
or less similar genetically due to the stochastic nature of segregation and 
recombination. However, the model assumes that if a large enough group of 
siblings were tested, the average percentage of segregating genes would be 
50%, which has also been experimentally confirmed.179 The model further 
relies on the assumption that both types of twins share environment to 
similar extent, and that there is no assortative mating. If genes influence a 
trait, there will be more pronounced twin similarity within monozygotic than 
within dizygotic pairs. By modeling twin covariance structures in 
monozygotic and dizygotic pairs, the variation in a phenotype is decomposed 
into additive genetics (A) - or narrow sense heritability, shared environment 
(C), and non-shared environment (E), where the latter captures remaining 
measurement error. This is also referred to as an ACE model. See Figure 3.2. 
 
 
 
* The variance in the trait of each twin is explained by the variance components additive genetics (A), shared 
environment (C), and non-shared environment (E). The magnitude of the associations between the variance 
components and the trait can be given as standardized regression coefficients (a, c, and e). Monozygotic 
twins are assumed to share all their genes, whereas dizygotic twins are assumed to share on average half of 
their segregating alleles. Both monozygotic and dizygotic twins are assumed to share environment to similar 
extent.
Figure 3.2. Path diagram of the classical twin model*
Trait 
Twin 1 
A C E 
a c e  
Trait 
Twin 2 
A C E 
a c e 
rA = 1 / 0.5 rC = 1 
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Sibling model 
In a similar way, the genetic and environmental relationship between full-
siblings and half-siblings can also be used to estimated the variance due to 
genetic or environmental factors. In a sibling model, monozygotic and 
dizygotic twins are assumed to share 100% and 50% of their additive genetic 
factors, whereas the corresponding values are 50% for full siblings, and 25% 
for half siblings. The shared environment is assumed to be completely shared 
by all sibling types except by paternal half siblings, that instead is assumed 
unshared because Swedish half siblings are much more likely to live with 
their mother.208 
Multivariate models 
Estimating the heritability using these models can be done for a single trait, 
i.e. a univariate model, or for multiple traits, i.e. multivariate models. A 
bivariate model is a multivariate model using two traits, and can be used to 
account for genetic and environmental overlap between two traits. One of 
many multivariate parameterization techniques is the Cholesky 
decomposition approach that enables the estimation of the phenotypic 
correlations between traits, as well as the genetic and environmental 
contributions to the correlations.209 See Figure 3.3. 
 
  
Figure 3.3. Path diagram of a Cholesky decomposition*
* The example only includes A and E factors. The variance in trait 2 is explained by additive genetics that also 
explain trait 1 (A1), and additive genetics that is unique for trait 2. The magnitude of the contribution is given by 
a11, a12, and a22. The same applies for non-shared environment (E1 and E2).
Trait 1 
A1 
a12 a11 
Trait 2 
A2 
e11 e12 e22 
a22 
E1 E2 
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 STUDY DESIGNS 4.
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4.1 STUDY I 
We identified individuals with bipolar disorder in the National Patient 
Register using a validated algorithm,206 and linked these individuals to the 
Swedish Prescribed Drug Register to identify incidences of dispensed 
prescriptions of antidepressant drugs (SSRIs, SNRIs, tricyclic- and tetracyclic 
antidepressants, and bupropion), and mood stabilizing drugs (lithium, 
valproate semisodium, and lamotrigine). To be included, we required an 
individual with bipolar disorder to have at least one prescription and 
dispensation of an antidepressant drug without any dispenses during the 
preceding year, consequently securing that this dispense signified the start of 
a treatment period. 
Antidepressant medication was the main exposure, and patients were 
stratified based on the simultaneous medication with mood stabilizers. To be 
categorized as a minimally adequate course of treatment with a mood 
stabilizer, an individual with bipolar disorder had to have dispensed a mood 
stabilizing drug at least two times in the year preceding the antidepressant 
treatment, of which at least one had to have been dispensed between 4 and 12 
months prior the antidepressant treatment start. To be categorized as not 
using a mood stabilizer, an individual with bipolar disorder was required not 
have any dispenses of mood stabilizers in the year preceding the 
antidepressant treatment start. If an individual in the antidepressant 
monotherapy group was prescribed a mood stabilizer, the follow-up was 
censored at the time of prescription. The occurrence of mania among the 
patients was obtained using discharge diagnosis codes for mania from the 
National Patient Register during the follow up from July 2005 through 2009.  
The association between antidepressant medications and the outcome mania 
were estimated by cox proportional hazards regression analyses where all 
patients serve as their own control, i.e. a within-individual model, thereby 
reducing confounding by differences between patients in genetic makeup, 
severity of the disorder, and environmental factors up until the start of follow 
up. We compared the individuals during, 1) a 9-month time period prior the 
treatment start, with 2) a 9-month time period following treatment initiation. 
See Figure 4.1. We accounted for deaths and migrations, and if the patient 
died, emigrated, or was diagnosed with schizophrenia during the second 
(treated) period, the follow up was censored at this time. To allow for 
assessment of both acute and long-term effects, interaction terms with split 
follow-up time (0-3 months, 3-9 months) was included in the statistical 
model. In a second analysis, we added mood stabilizer medication as an 
additional interaction term to establish differences depending on 
simultaneous mood stabilizer use. 
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4.2 STUDY II 
Classical twin study 
We initially identified twin mothers who reported having given birth to a 
living child, and who completed the lifetime Edinburgh Postnatal Depression 
Scale in the Screening Across the Lifespan Twin study: the Younger (SALTY). 
Mood symptoms both during pregnancy and within six months postpartum 
were assessed using the lifetime version of the Edinburgh Postnatal 
Depression Scale, and a score of 12 or above was used to define a binary 
outcome of perinatal depression. The variance in perinatal depression due to 
genetic or environmental factors was estimated using the classical twin 
methodology and a univariate model. Since shared environment, the C 
component, was found to be statistically insignificant, an AE model where C 
was fixed at zero was fitted instead of an ACE model. 
Sibling design 
A population-based sample from Swedish national register data was further 
included to assess variance in perinatal depression and non-perinatal 
depression due to genetic and environmental factors in a larger and more 
generalizable setting. The sample included all parous women who had given 
birth to their first child after 1973, and fulfilled the criteria of being born in 
Sweden, not having emigrated and moved back to Sweden more than once, 
and had to have at least one sister fulfilling the same criteria. A design that 
included up to four full or half-siblings per nuclear family was used. The 
sample included monozygotic and dizygotic twins, full siblings, and maternal 
and paternal half-siblings. Depression was assessed using treatment contacts 
for depression. The conception date was calculated using the birthdate of the 
child and gestational age at delivery, both retrieved from the Medical Birth 
Register, and the perinatal period was defined as any point from estimated 
-365 days -274 days
Antidepressant
medication start
* The design permits within-individual comparisons of mania after initiation of an antidepressant treatment with 
a preceding non-treatment period. The follow-up time is divided into 0–3 months and 3–9 months to assess 
acute (switch) effects and longer-term effects.
+274 days
Antidepressant un-treated period
3-9 months
Figure 4.1. Design of Study I*
0-3 months 0-3 months 3-9 months
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date of conception through six-months postnatally. Perinatal depression was 
further defined as at least one inpatient or outpatient treatment contact for 
depression according to the above listed diagnosis codes within a perinatal 
period, whereas non-perinatal depression was defined as depression at any 
other time of life. We further separated perinatal period into an antenatal 
period covering the pregnancy, and a postnatal period of 12 months to allow 
heritability estimation of these separate periods. 
The relative importance of genetic and environmental effects was estimated 
in up to four female siblings simultaneously in family clusters. The family 
clusters included siblings who shared at least one parent, permitting both full 
and half-siblings within a single family. No known sibling relations existed 
between clusters and the individual sisters were not included in more than 
one cluster. If individuals were belonging to half-sibships in more than one 
family, only the largest family was included to avoid duplicate entries. Any 
family consisting of more than four individuals was reduced to four 
individuals through random selection. 
Similarly as in the classical twin design, monozygotic and dizygotic twins 
were assumed to share 100% and 50% of their additive genetic factors, and 
the corresponding values were 50% for full siblings, and 25% for half siblings. 
The shared environment was modeled to be completely shared by all sibling 
types except paternal half siblings, were it was assumed unshared because 
Swedish half siblings are much more likely to live with their mother.208 
Individual environmental factors were assumed unique to each individual. 
These assumptions formed the basis on which we could determine the 
expected correlation structures for each specific type of family cluster 
depending on the sibling types included. We fitted univariate models where 
the variance in each disease was modeled separately to be due to additive 
genetics, shared environment, and non-shared environment. Similar to the 
twin model, shared environment in perinatal depression, or the C 
component, was found statistically insignificant whereby an AE model 
instead was fitted where the C component was fixed at zero. We further fit 
bivariate models where the variance and covariance in each trait were 
simultaneously modeled to be due to additive genetics, shared environment, 
and non-shared environment. A Cholesky decomposition approach was used 
to estimate how much of the variance in one disorder that could be attributed 
to each of the factors in common with the other disorder, and factors unique 
to perinatal depression.209 As this was modeled in a regression framework, 
we adjusted the prevalences for whether the family included half-siblings as 
well as for birth year (both linear and squared), and further adjusted non-
perinatal depression for time at risk (linear and squared), and perinatal 
depression for number of offspring. 
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4.3 STUDY III 
We identified live and non-twin childbirths from April 1st 2006 to the end of 
2009 from the Swedish Medical Birth Register. The register contains the 
birthdate and the gestational age, and this information was used to estimate 
the conception date. The cohort was further linked to the Multi-Generation 
Register to create a within-family sub-sample through identification of both 
parents of each child, consequently allowing identification of full-sibling 
relationships. To allow informative within-family comparisons, the full-
siblings had to be discordant for the SSRI exposure. 
Exposures 
Treatment with SSRIs was determined by linking the cohort to the Swedish 
Prescribed Drug Register and allowed identification of all Swedish prescribed 
and dispensed prescription drugs since July 1st 2005. Using the Anatomical 
Therapeutic Chemical Classification System (ATC), we identified 
dispensations of SSRI medication around the time of pregnancy. A 
dichotomous exposure variable was created based on SSRI dispensation 
patterns: 1: no dispensations from three weeks before pregnancy until the 
childbirth (no SSRI exposure), and 2: more than one dispensation between 
conception and childbirth, or one dispensation within the pregnancy period 
and at least one more dispensation within 6 months before or after the 
dispensation during pregnancy (SSRI exposure). Depression was identified 
in the National Patient Register that provides information on Swedish 
psychiatric specialist inpatient care and outpatient care. Depression was 
defined as at least one treatment contact for depression between conception 
and delivery. A categorical exposure variable was produced based on SSRI 
treatment and hospital care for depression (0: No SSRI exposure, and no 
hospital care for depression during pregnancy. 1: SSRI exposure. 2: At least 
one treatment contact for depression during pregnancy, and no SSRI 
medication).  
Outcomes 
We used information from the Medical Birth Register to create the outcome 
variables studied. This included gestational age at birth (days) and preterm 
birth (gestational age at birth below 259 days) calculated through 
standardized ultrasound measurements at pregnancy week 16-18, birth 
weight (grams), birth length (centimeter), and birth head circumference 
(centimeter). Since there is a strong correlation between birth size and the 
gestational age at birth, the growth outcomes were standardized by 
gestational age at birth using the mean and standard deviation of children in 
the cohort born within the same gestational week. The standardized values of 
birth weight displayed a correlation of 0.98 with a previous method based on 
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ultrasound measurements at different gestational ages during pregnancy in 
healthy children.36 
We adjusted the analyses for factors that may confound the associations. The 
body mass index (BMI) of the mother was calculated (weight in kilograms 
divided by height in meters squared) based on weight and height measured 
at the first antenatal care visit and provided by the Medical Birth Register, 
and was divided into four categories (<18.5, 18.5-25, 25-30, >30). The height 
of the mother was also used as a separate covariate. The birth order was 
included as a covariate since there may be systematical differences for using 
SSRI depending on the mother's parity at the specific pregnancy. Previous 
psychiatric history was established using any hospital contact with a 
psychiatric diagnosis from the National Patient Register prior the specific 
childbirth using ICD 7-10 revisions. The mother's age at delivery (years), and 
smoking status (1: no smoking. 2: 1-9 cigarettes per day. 3: >9 cigarettes per 
day) at first antenatal care visit, was obtained from the Medical Birth 
Register. The highest completed education (1: compulsory school. 2: upper 
secondary school. 3: post secondary education less than three years. 4: 
university three years or more) at the time of delivery was obtained by linking 
the subjects to the Swedish longitudinal integration database for health 
insurance and labour market studies. 
In the full cohort, the association between prenatal exposure of SSRI 
treatment, or depression without SSRI treatment, and the continuous 
variables birth weight, birth length, birth head circumference, and 
gestational age at birth were estimated by linear regression analyses, while 
the binary outcome preterm birth was analyzed by logistic regression. 
Children without SSRI or depression exposure was used as the reference 
group and the analyses were adjusted for all the covariates. Robust standard 
errors were used, as several children from the same mother were included in 
the analysis. The within-family analyses were done by estimating models 
with a fixed effects regression estimator (STATA xtreg statement, within 
mother) for continuous variables and conditional logistic regression for 
preterm birth. This design allows automatic adjustments for all covariates 
that did not change between the births, consequently adjusting for a wide 
range of unmeasured confounding factors that are shared within the family. 
In these analyses we included all families with at least two siblings discordant 
for SSRI exposure, but if more than two siblings were identified they were 
also included. The children not exposed to depression or SSRI was used as 
the reference group. 
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4.4 STUDY IV 
We established a nation-wide cohort of all mothers and childbirths over a 37-
year period in Sweden using the Medical Birth Register. Fathers are not 
included in the Medical Birth Register, but were identified by linking the 
cohort to the Multi-generation Register. Primary care data was only available 
for Stockholm County, and only covered a six-year period. Therefor, a sub-
sample of Stockholm County residents was created by linking the full cohort 
with the Small Area Marketing Statistics (SAMS) register that contain annual 
information on residential area. Only individuals living in Stockholm County 
throughout the six-year period was included to reduce the risk of 
misclassification. 
All individuals in the cohort, including both mothers and fathers, were linked 
to the National Patient Register, allowing identification of healthcare 
contacts. At least one treatment contact with a diagnosis code for depression, 
anxiety disorders, or any psychiatric disorder was used. 
Patterns of healthcare around the perinatal period, and compared to other 
periods of life, were studied using two approaches. First, the occurrence 
during a period (pregnancy, or the whole perinatal period) was contrasted to 
the occurrence during adjacent periods before and after of equal length as the 
period compared. If an adjacent period overlapped with the period belonging 
to a sibling, the period was not used. See Figure 4.2. 
 
 
 
 
* The occurrence during a period was compared to adjacent periods of equal length before and 
after. This was done for the pregnancy, which was contrasted to an equally long period prior 
conception, and after childbirth, and for the whole perinatal period, which was contrasted to a 
period equally long as the whole perinatal period prior conception, and after the perinatal period - 
thus starting six months postpartum. The given 15 and 9 months in this figure is an approximate 
and could vary between individual pregnancies. 
Figure 4.2. Comparisons of adjacent periods in Study IV*
Pregnancy
9 months
Prior pregnancy
9 months
After pregnancy
9 months
Conception Childbirth
Perinatal period
15 months
After perinatal period
15 months
Prior perinatal period
15 months
Conception Childbirth
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A second approach was applied to avoid the inherent problem of potential 
influences by the fixed calendar time order of adjacent periods before and 
after. This approach was used to study the whole perinatal period only, and 
each subject was grouped with the other subjects in the cohort matched on 
birth year and sex, and the perinatal period(s) belonging to each subject were 
permutated, i.e. randomly swapped between subjects. This provided each 
parent the perinatal time period(s) belonging to an age and sex matched, but 
otherwise randomly selected parent. These permuted periods covered time-
periods at random, but as opposed to simply providing each parent 
randomized periods, the permuted periods originate from another individual 
and represent the time of life were other individuals born the same year 
would have children. Furthermore, by maintaining the natural patterns of 
childbirth, the permuted periods represent a biologically possible 
distribution, as opposed to randomized periods that could overlap in 
biologically impossible ways. See Figure 4.3. Using this procedure, the 
occurrence of diagnoses within the perinatal period(s) could be contrasted to 
that of non-perinatal period(s) in the same person, as opposed to using a 
control group that could have a totally different liability. Differences in 
occurrences were described descriptively, and tested using logistic regression 
with robust standard errors clustered on the parent (adjacent periods), by 
chi-squared tests (permuted periods). 
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Woman 1
Woman 2
21
21
19 20
19 20
18
18
AFTER PERMUTATION
43 4438 39 40 41 42
Age
Woman 1
Woman 2
Age 22 23 24 25 26 27 28 29 30 31
28272625 43 4438 39 40 41 4233
Figure 4.3. Example of permutation of perinatal periods*
3029 322423 34 35 36 3731
* Woman 1, born 1955, has been pregnant two times: the first time at age 27 and the second 
time at age 32. After permutation, she has randomly been assigned the perinatal periods of 
woman 2. Woman 2 is also born 1955 but has been pregnant three times, at age 24, 29, and 
36. This gives woman 1 three perinatal periods, or permuted periods, originally belonging to 
woman 2, and none of these overlap with her original perinatal periods. However, they are 
still within the age range where most women born that year get pregnant.
PRIOR PERMUTATION
22
32 33 34 35 36
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 RESULTS AND 5.
DISCUSSION 
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5.1 STUDY I RESULTS 
We identified 31,916 individuals that met our criteria for bipolar disorder, 
where 22,339 individuals (70%) had an antidepressant drug dispensed 
between the 1st of July 2005 and the 31st of December 2009. Among these 
subjects, 3,240 individuals passed the criteria for initiating an antidepressant 
treatment during the follow up. The mean age of the included individuals was 
52 years and 61% were women. 
 
5.1.1 ANTIDEPRESSANTS AND THE RISK OF MANIA 
We initially analyzed the full cohort of 3,240 bipolar disorder patients, 
placing the patients treated on an antidepressant monotherapy and those on 
a combined therapy of an antidepressant and a mood stabilizer together. This 
revealed no increased risk of mania within the first three months of 
treatment (the hazard ratio [HR] for the 0- to 3-month period was 0.91, 95% 
confidence interval [CI] 0.69 - 1.21; non-significant). For the long-term 
period, a decreased risk of mania was observed (HR 0.68, 95% CI 0.50-0.92; 
p=0.01). 
5.1.2 MOOD STABILIZER TREATMENT 
Next, we separated out the 1,117 patients in the full cohort that had received 
an antidepressant monotherapy (34.5%). In this sub-sample the risk of 
mania was significantly increased within the first three months of treatment 
(HR 2.83, 95% CI 1.12-7.19, p=0.028), but not in the long-term period (HR 
0.71, 95% CI 0.23-2.26, p=0.57). 
Among the remaining patients, 1,641 (48%) had received a mood stabilizer in 
conjunction with the antidepressant according to our criteria. Contrary to the 
monotherapy treated patients, these patients did not display an increased 
N %
1,270 60.8
1,555 48.1
Unmarried 1,222 38.2
Married 945 29.5
Divorced 873 27.2
Widowed 163 5.1
1,068 33.3
172 5.4
< 25 years 197 6.1
25-39 years 651 20.1
> 39 years 2,384 73.8
 Table 5.1.  Characteristics of the patients at baseline (n=3,240).
Civil status
Age group
Employed
Living in a metropolitan area
In school
Characteristic
Female
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risk of mania within the first three months of treatment (HR 0.79, 95% CI 
0.54-1.15, p=0.214), and a decreased risk of mania in the long-term period 
(HR 0.63, 95% CI 0.42-0.93, p=0.020). 
We also observed differences in mania rates, i.e. number of mania events 
divided by number of individuals in the specific group, between the separated 
groups. The antidepressant monotherapy treated patients had lower rates 
altogether; without antidepressant: 0.006 and 0.010 in the 0-3 months and 
3-9 months respectively; with antidepressant: 0.015 and 0.006 in the 0-3 
months and 3-9 months respectively, while the patients on a combined 
treatment of an antidepressant and a mood stabilizer displayed higher rates; 
without antidepressant: 0.041 and 0.065 in the 0-3 months and 3-9 months 
respectively; with antidepressant: 0.036 and 0.030 in the 0-3 months and 3-
9 months respectively. See Figure 5.1. 
 
 
 
 
* Mania rate is calculated for each group by dividing no. of mania diagnoses by no. of patients in 
the specified group.  Patients treated with an antidepressant monotherapy is represented by the 
lower part under a full line, and the patients with an antidepressant in conjunction with a mood 
stabilizing medication is represented by the upper and lower part combined under a dotted line. 
Here, all mania diagnoses are considered, in contrast to the COX regression analysis where only 
the first diagnosis in each period is considered. The COX regression further considers time to 
event in the estimation of the hazard ratio, which is not described by this figure.                    
0.006
0-3 months 3-9 months 0-3 months 3-9 months
0.006 0.010
0.015
0.065
0.041
Antidepressant
 medication start
Figure 5.1. Rates of mania among individuals with bipolar disorder*
0.030
0.036
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5.2 DISCUSSION OF STUDY I 
The results from this study suggests that antidepressant induced switching 
may be confined to patients on an antidepressant monotherapy. Patients on a 
concomitant mood stabilizing treatment instead displayed a decreased rate of 
mania after antidepressant medication. By surveying the overall rate of 
mania in these two groups, we observed more mania among the mood 
stabilizer treated patients overall. Nonetheless, we observed no increase in 
mania occurrence after the antidepressant medication start in this particular 
group, even though this patient group clearly exhibited a higher occurrence 
of mania. This is in line with many previous studies that have found an 
association between antidepressant monotherapy and manic 
switching,156,158,160-162,210 and lends support to recent recommendations that 
caution against the use of an antidepressant monotherapy in bipolar disorder 
patients.27,166 The study also demonstrate that antidepressant medication is 
common among Swedish bipolar disorder patients, with 70% of all identified 
patients nation-wide having received an antidepressant medication anytime 
during the total 4.5 years of follow up. Furthermore, half of these received an 
antidepressant alone and not in combination with a mood stabilizing 
treatment. 
Name N % N % N %
Citalopram 519 18.8 244 21.8 275 16.8
Sertraline 456 16.5 184 16.5 272 16.6
Mirtazapine 444 16.1 199 17.8 245 14.9
Escitalopram 358 13.0 104 9.3 254 15.5
Venlafaxine 189 6.9 76 6.8 113 6.9
Duloxetine 176 6.4 69 6.2 107 6.5
Fluoxetine 158 5.7 59 5.3 99 6.0
Amitriptyline 140 5.1 65 5.8 75 4.6
Bupropion 140 5.1 43 3.9 97 5.9
Paroxetine 66 2.4 31 2.8 35 2.1
Mianserin 50 1.8 12 1.1 38 2.3
Clomipramine 46 1.7 20 1.8 26 1.6
Nortriptyline 7 0.3 4 0.4 3 0.2
Maprotiline 4 0.2 4 0.4 0 0.0
Imipramine 2 0.1 0 0.0 2 0.1
Trimipramine 2 0.1 2 0.2 0 0.0
Fluvoxamine 1 0.05 1 0.1 0 0.0
 Table 5.2. Specific antidepressants dispensed a
a The specific antidepressants and the number and percent of individuals with the specific antidepressant 
dispensed at the start of the treatment period.  Due to strict inclusion criteria to classify patients as being 
on a concurrent mood stabilizer treatment or not, 482 patients from the full sample with ambiguous mood 
stabilizer use were not classified as either on monotherapy, nor concurrent mood stabilizer treatment.
Antidepressant 
monotherapy group
(N=1,117)
Antidepressant + mood 
stabilizer group
(N=1,641)
Full sample
 (N=3,240)
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The study also demonstrates that the underlying differences between patients 
with the same diagnosis but on different medication can be pronounced. See 
Figure 5.1. This is important, as it demonstrate that a 
pharmacoepidemiological approach that does not take the disorder history 
into account may risk drawing incorrect conclusions. If we would only survey 
the occurrence of mania after the antidepressant medication initiation, we 
would end up observing more mania among the patients being treated with a 
mood stabilizer in combination with the antidepressants, as compared to the 
patients on an antidepressant monotherapy. See Figure 5.2 below. However, 
this is a classic case of confounding by indication, where the patients on the 
double therapy are being treated with a mood stabilizer medication just 
because they likely suffer from more mania overall. This may have been the 
case in a big meta-analysis by Tondo et al. where patients on a mood 
stabilizing treatment were found to have equally or more mania than patients 
not treated with a mood stabilizer.211 By allowing our study to compare the 
rate of mania in periods prior the antidepressant treatment start with periods 
after the initiation, we expand our view and allow the model to take the 
disorder history into account. Moreover, by doing this within-individual 
framework, we further take individual-specific variation into account and 
automatically adjust for several otherwise unmeasured confounding factors. 
 
 
0.065
0.041
Antidepressant
 medication start
Figure 5.2.  Rates of mania among individuals with bipolar disorder*
0.030
0.036
*  If only the time after medication start is considered, one may conclude that mania is more 
common among mood stabilizer treated individuals. However, in an observational setting 
individuals with a mood stabilizer treatment is likely more prone to suffer from elevated mood. If 
a preceeding period is taken into account, it is apparent that the mood stabilizer treated group 
has overall more mania, and that mania is reduced after antidepressant treatment initiation.
0.006
0-3 months 3-9 months 0-3 months 3-9 months
0.006 0.010
0.015
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Switching in bipolar disorder is a controversial topic and these findings were 
not received without some debate. Ostacher et al. sent a letter to the editor of 
the American Journal of Psychiatry, questioning a number of aspects of the 
study and the reported observations.212 We were allowed to respond to 
Ostacher et al. in a response letter also published in the Journal,213 and even 
if we did not agree to some of the points made by the authors of the letter, the 
letter and our response allowed a public discussion of important topics and 
considerations that were not clear in the initial publication.214 Firstly, 
Ostascher et al. pointed out that the hazard ratio among the antidepressant 
monotherapy treated patients was supported by a low event rate, that there 
were few patients that actually switched, and that out of a hundred 
antidepressant monotherapy treated patients only one would experience a 
manic switch. Based on this, Ostacher et al. proclaimed that they did not 
agree with our conclusions, and particularly not that antidepressants are 
associated with mania. However, as we also pointed out in our response 
letter, the antidepressant monotherapy treated patients have a different 
underlying mania rate, and likely a different risk of manic switching. In this 
observational setting, this is an example of confounding by indication, and 
the monotherapy group is not representable for all bipolar disorder patients. 
That is, it is not likely that a similar hazard ratio would be observed if the 
patients with more mania, and therefor a mood stabilizing treatment, were 
denied their concomitant mood stabilizer medication and put on an 
antidepressant monotherapy. These patient with a higher risk of mania 
would likely experience more switching, thereby increasing the hazard ratio. 
The letter further allowed us to point out an important detail of our study 
that for a number of reasons did not make it to the final publication. Due to 
the observational nature of the study, we were very cautious of potential 
interpretations and assumptions. This led to strict inclusion criteria, and 
hence excluded a large number of potential subjects. One of these potential 
interpretations was with regards of dispensations of mood stabilizer 
treatment after antidepressant medication initiation in the monotherapy 
group. This group was formed based on the criterion of having no mood 
stabilizer treatment in the year preceding the antidepressant medication 
start. As these patients were followed after the initiation of the 
antidepressant treatment, some of them would develop mania and be 
censored at that time. However, quite a lot of these patients would dispense a 
mood-stabilizing drug in this antidepressant treated period, without 
receiving a mania diagnosis. This could be interpreted either as a cautionary 
measure by a treating clinician to prevent elevated mood. But it could also 
signify that the patient indeed was experiencing mood elevation, and that the 
sudden prescription and dispensation of this extra medication was an 
indication of a manic switch. We felt that this was too speculative and did not 
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want to make such an assumption. Instead, all patients in the monotherapy 
group were censored if they received a mood stabilizer medication after 
antidepressant treatment start. If, however, the sudden prescription and 
dispensation were to be classified as a manic switch, the hazard ratio would 
have risen to 16.3 (95% CI=7.2–37.2) in the 0- to 3-month period and to 11.7 
(95% CI=5.1–26.9) in the 3- to 9-month period after the antidepressant 
treatment start. 
Moreover, as we also point out in the response letter, we lack primary care 
data for these patients, and therefor may fail to detect episodes of elevated 
mood diagnosed in a primary are setting exclusively, although the extent of 
this happening is not known at the moment. It is also important to note that 
just like a sudden dispensation of a mood stabilizing treatment may signify 
elevated mood even without a mania diagnosis, there could also be a number 
of patients that experienced elevated mood and stopped the antidepressant 
treatment, without neither getting a mood stabilizing treatment, nor a mania 
diagnosis. 
Another important limitation in this setting is that of adherence. Our study 
relies on prescription and dispensation data, and we define the start of an 
antidepressant treatment as at least one dispensation. This dispensation has 
to be preceded by a year of no dispensations, thereby indicating that this is 
indeed the start of a new treatment. However, we have no way to knowing 
whether the medication was actually consumed. In other settings, a 
continuous pattern of dispensations may be used, as antidepressants are 
commonly used over longer periods of time.215-217 It is therefore more likely 
that a continuous dispensation pattern denotes consumption, as compared to 
a single dispensation. In our study setting, however, requiring a continuous 
pattern creates selection bias, as this criterion effectively excludes anyone 
that would chose to end the medication prior having the chance to dispense a 
second prescription. Therefor we have to rely on a single dispensation, and 
there is a possibility that this dispensed drug was not consumed, thereby 
making an antidepressant induced manic switch impossible and potentially 
underestimate the risk. 
All these things considered, it is likely that the low rate of manic switch that is 
pointed out in the letter is a conservative estimate, and that the actual risk is 
higher. But even if the actual number is higher than our study estimates, 
Ostascher et al. points out an important issue. Whether or not to prescribe a 
concurrent mood stabilizing treatment with an antidepressant medication to 
bipolar disorders patients is still complicated. Lithium and valproaic acid 
have numerous side-effects,218,219 and adding these drugs to an 
antidepressant medication may induce further side-effects through 
interactions. It is possible that switching is confined a subset of bipolar 
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disorder patients, and that there are patients that would never switch, but 
that would suffer from a mandatory addition of a mood stabilizing 
medication in combination with the antidepressant. However, as there are 
currently no ways to distinguish these patients, and switching is associated 
with worse disorder outcomes,220 whether to prescribe this double treatment 
or not remains complicated. 
Another limitation of this study is the grouping of different antidepressant 
drug categories. It is possible that a specific category is causing all or a 
majority of the switches. We tried to address this, but groups based on 
specific drug prescriptions yielded sample sizes that were too small. Most 
patients received SSRIs and too few patients were treated with SNRIs, TCAs, 
tetracyclic antidepressants, or bupropion to allow for meaningful 
comparisons. Similarly, the lack of statistical power prevented us from 
conducting meaningful analyses of the type of mood stabilizing drugs 
separately, and just like the example above with antidepressants, it is 
possible that a specific type of mood stabilizer is possessing all or a majority 
of the switch preventing properties. Another aspect of the mood stabilizing 
drugs studied is the lack of atypical antipsychotics like quetiapine or 
olanzapine in the study. These drugs have anti-manic properties and are also 
used to treat mania. However, due to their side-effect profile, these drugs 
may not be suitable for long-time treatment, and this was also reflected in 
our data. If we singled out the patients in the cohort whose mood-stabilizing 
treatment only consisted of atypical antipsychotics (N=112), we noted a large 
rise in mania just prior the antidepressant treatment start. This indicated 
that these patients were different and that the atypical antipsychotic 
medication likely reflected an acute treatment. Because of the deviation of 
this group, we chose not to allow mood-stabilizing treatment to be defined 
based on atypical-antipsychotic use. However, to not create a selection effect, 
we did not prohibit the mood-stabilizer treated patients from also having 
atypical antipsychotics dispensed. 
Furthermore, it can be worth noting that our study did not survey the 
efficiency of antidepressants in treating bipolar depression. This is another 
related controversial topic,154,155 and we initially discussed including this 
during the planning of the study, but reached the conclusion that it is not 
possible to address this question with the current design. The problem lies in 
the nature of how depression diagnoses are used in our healthcare system: 
When prescribed an antidepressant, the patient will be diagnosed with the 
indication for the drug - in this case depression. We would then require a 
time point at which the patient is recovered. But time to follow up visits 
depends on several other factors than the response to the drug: resources, the 
individual doctor, the type of drug prescribed, to name a few. Also, the 
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diagnosis that indicates remission, F31.7: bipolar disorder without current 
affective symptoms, is rarely used and patients tend to continue on the 
bipolar depression diagnosis, F31.3-4, as long as they receive antidepressant 
treatment despite recovering. This is opposite to how we use the mania 
diagnosis in this study where we know that that the patient has received an 
antidepressant most likely for depression. The follow up visit should hence 
not routinely lead to a mania diagnosis. 
 
5.3 STUDY II RESULTS 
5.3.1 THE TWIN COHORT 
We identified 3,427 twin mothers that had completed the lifetime version of 
the Edinburgh Postnatal Depression Scale. Among these, 1,517 were 
monozygotic twins and 1,991 were same-sex dizygotic twins. In the twin 
cohort, where perinatal depression had been assess with the lifetime version 
of the Edinburgh Postnatal Depression Scale, we observed an lifetime 
occurrence of perinatal depression of 7.6%.  
Univariate heritability 
After initially fitting an ACE model that revealed the variance due to shared 
environment statistically insignificant, we instead fitted an AE model where 
the C-component was fixed at zero. Based on the lifetime version of the 
Edinburgh Postnatal Depression Scale, the heritability of perinatal 
depression among the twin mothers were estimated at 54% (95% CI 35-70%), 
with the remaining variance explained by non-shared environment (46%, 
95% CI 31-65%). See Figure 5.3. We observed a tetrachoric correlation of 
0.55 (standard error: 0.09) among the monozygotic twins, and a tetrachoric 
correlation of 0.22 (standard error: 0.14) among the dizygotic twins. 
 
0% 100%
Figure 5.3.  Variance in perinatal depression using the classical twin model
Additive genetics Non-shared environment
54% 46%
 
5.3.2 THE SIBLING COHORT 
By linking Swedish national registers, we identified 580,006 female siblings 
that had given birth to at least one child between the beginning of 1973 and 
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the end of 2009. These siblings stemmed from 260,384 unique families and 
included 313,632 pairs of full-sisters, 33,931 pairs of paternal half-sisters, 
28,568 pairs of maternal half-sisters, 2,225 pairs of monozygotic twin sisters, 
and 2,104 pairs of dizygotic twin sisters. We identified 1,572 twin sisters that 
overlapped between the twin cohort and the sibling cohort. The observed 
occurrence of perinatal depression in the sibling cohort, using treatment 
information rather than a questionnaire, was 0.6%.  
Univariate heritability 
Just like in the twin model, the variance in perinatal depression due to 
shared environment was statistically insignificant, and an AE model where 
the C-component was fixed at zero was fitted. Using the sibling cohort and 
treatment information data, we estimated the heritability of perinatal 
depression at 44% (95% CI, 35-52%), with the remaining variance explained 
by non-shared environment only. In the same sample, we estimated the 
heritability of non-perinatal depression at 32% (95% CI, 24-41%), with the 
remaining variance explained by shared environment (6%; 95% CI, 2-10%), 
and non-shared environment (62%; 95% CI, 57-66%). See Figure 5.4. 
 
 
 
Dividing the perinatal period revealed little difference between antenatal 
depression, with a heritability estimated at 37% (95% CI, 27-47%) and 
remaining variance due to non-shared environment, and postnatal 
depression, with a heritability estimated at 40% (95% CI, 31-49%) and 
similarly the remaining variance also due to non-shared environment. 
Bivariate heritability 
0% 100%
6%
0% 100%       Shared environment
Non-shared environment
32%
Additive genetics
62%
Figure 5.4. Variance in perinatal depression (upper) and non-perinatal depression (lower) using 
the sibling model
Additive genetics Non-shared environment
44% 56%
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We used a multivariate model to estimate the overlap between the two types 
of depression. When applying this model to explain the variance in perinatal 
depression, the C-parameters, except C unique for non-perinatal depression, 
was estimated close to zero and did not provide a significant contribution to 
the variance. We instead fitted an AE model where these parameters were set 
to zero, and estimated that 14% of the total variance (or 33% of the genetic 
variance) in perinatal depression was unique for perinatal depression and 
not in common with non-perinatal depression. See Figure 5.5. 
 
 
 
5.4 DISCUSSION OF STUDY II 
This study is the largest and most comprehensive genetic epidemiological 
study of perinatal depression yet reported. But more importantly, it is the 
first bivariate heritability study that explores the genetic overlap between 
depression specifically around the time of pregnancy with depression at any 
other time, and the second ever study to estimate the heritability of 
depression at this particular time.221 As such, the study estimated the 
heritability of perinatal depression at 54%, using the classical twin model and 
the lifetime Edinburgh Postnatal Depression Scale, and at 44% when the 
sibling model and healthcare data were used. Moreover, the sibling model 
using treatment data estimated the heritability of non-perinatal depression at 
32%, and a bivariate approach demonstrated that a third of the genetic 
contribution is unique to perinatal depression and not shared with non-
perinatal depression. This implies only partially overlapping genetic 
etiologies for perinatal depression and non-perinatal depression, and may 
indicate that depression treated in the perinatal period is not only different 
based on when in life the depression is diagnosed, but may also constitute a 
subtype of depression with slightly different genetic underpinnings. 
Differences regarding timing of onset of depressive symptoms in pregnancy 
(antenatal depression) versus postpartum (postnatal depression) has been a 
Unique
14%
0% 100%
* No contribution from shared environment.
Figure 5.5. Variance in perinatal depression due to factors unique for perinatal depression, and due to 
factors in common with non-perinatal depression*
Additive genetics Non-shared environment
In common
28%
In common
16%
Unique
42%
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central topic in recent work.222 Our study allowed division of the perinatal 
period into an antenatal period and a postnatal period. However, to allow 
meaningful comparisons, the postnatal period had to be extended to 
incorporate enough cases to permit the heritability to be estimated. Using 
this approach, the heritability of antenatal depression was estimated at 37% 
and the heritability of postnatal depression was estimated at 40%. 
Furthermore, the variance of both antenatal and postnatal depression 
separately displayed a similar pattern as the variance of perinatal depression 
as a whole, with variance explained by additive genetics and non-shared 
environment of similar size, without contribution of shared environment. 
However, in the sibling model, the definition of perinatal depression, 
antenatal depression, and postnatal depression is based on timing of 
diagnosis. A diagnosis within the timeframe of any of these periods is used to 
define the type of depression, and this somewhat blunt definition constitutes 
a limitation of the study. It is, for instance, possible that a woman had 
depression prior becoming pregnant, and that the a depression diagnosis that 
arose from a planned revisit with the treating clinician is defined as perinatal 
depression and assumed different from non-perinatal depression in our 
study. This topic was investigated during the development of the study, and 
we tried to build an algorithm that would take patterns of previous 
healthcare contacts into consideration. However, we realized that without a 
proper validation study, it would be difficult to justify the use of this 
algorithm, which could potentially introduce bias. Instead we opted to keep 
the blunt definition, even though the actual depression onset was not known. 
But, even if a depression diagnosis is the first one in a long time, preceded by 
years of no diagnoses, the diagnosis date may still not represent the date of 
the onset, as a number of factors could act as barriers to healthcare seeking 
during this period of life and thereby delay treatment.72,87,88,92,93,223 Therefor, 
hurdles to treatment seeking may delay healthcare until after the postnatal 
period, and consequently define perinatal depression as non-perinatal 
depression. Conversely, a depression diagnosis within the perinatal period 
may in reality originate from a non-perinatal period and also be mis-
classified. Furthermore, depression can occur anytime throughout life and 
appears to have numerous underlying mechanisms,9,51 making it is possible 
that a depression starting within a perinatal period has underlying causes 
that are not connected to the pregnancy or childbirth in any other way than 
occurring during this specific timeframe, and that stochastic variation 
influenced the real underlying causes to coincide with the perinatal period. 
Nonetheless, we do detect differences between our two main definitions of 
depression, suggesting that at least a portion of the individuals with a 
depression diagnosis within the perinatal period may have had an onset 
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during this timeframe, and that this onset could denote a subtype of 
depression. 
This also puts the observed difference into perspective. Due to the potential 
misclassification of perinatal depression that originated in a non-perinatal 
period, our estimates may be diluted. If a more precise method of definition 
existed that allowed less misclassification, the observed difference may be 
larger. Furthermore, this potential misclassification between definitions due 
to timing of onset is likely affecting our division of antenatal and postnatal 
depression, and more precise information on onset in either period may 
reveal larger differences between the two periods. 
The study also estimated the heritability of perinatal depression at different 
sizes depending on the type of model used. In the classical twin model using 
the lifetime Edinburgh Postnatal Depression Scale, the heritability was 
estimated at 54%, whereas in the sibling model using healthcare data the 
heritability was estimated at 44%. The two designs also display marked 
difference in observed occurrence of perinatal depression with 0.6% in the 
sibling model and 7.6% in the twin model. However, the heritability 
estimates are similar and the confidence intervals overlap, and both 
estimates follow the same pattern with variance only due to additive genetics 
(A) and non-shared environment (E), as opposed to the variance in non-
perinatal depression that was also affected by shared environment (C).  This 
is consistent with that both approaches capture the same underlying liability 
for perinatal depression. The different methodologies likely explain the 
different observed occurrence rates; self-report in the twin model, and 
register based healthcare contacts in the sibling model. Therefor, the sibling 
design did not include women who did not seek treatment for perinatal 
depression but who would report symptoms on a self-report questionnaire. 
Additionally, it may be argued that the depression captured using the 
Edinburgh Postnatal Depression Scale and depression captured from 
specialist healthcare are of different severity. However, if the assumption of 
normally distributed liability and equal-environments hold true, this should 
not affect the estimates. That is, if the risk for a trait studied is normally 
distributed, different cut-offs on a scale that measures this risk will result in 
corresponding cut-offs in the normal distribution and capture the same 
underlying liability. Key assumptions of normally distributed liability and 
equal-environments have strong empirical support.224 
The definition of perinatal depression among the twin mothers in the twin 
model was based on a score of 12 or above on the lifetime version of the 
Edinburgh Postnatal Depression Scale, which is a commonly used 
cutoff.76,202,225,226 If a low score on the scale, and thus few depressive 
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symptoms, is the most common state in a population then the start of this 
scale will likely begin around the center of the bell curve. For every step up on 
the scale, i.e. increased depression severity, fewer individuals will be detected 
and the bell curve gets flatter. If the assumption of normally distributed 
liability holds true, then adjusting the cutoff should not affect the heritability 
estimate, as we should capture the same liability. Increasing or decreasing 
the cut-off still implies comparison of less depressed individuals with more 
depressed individuals. 
Table 5.3 below provides results from analyses using both decreased and 
increased thresholds on the Edinburgh Postnatal Depression Scale. If the 
assumption of underlying normally distributed liability hold true, the 
heritability estimates should not change, which is what we observe. This 
further support that potential differences in disorder severity between the 
two models different perinatal depression definitions does not constitute a 
barrier to capture the same underlying liability. 
 
The difference in the heritability estimates of perinatal depression between 
the twin model and the sibling model may instead be due to differences in 
samples and methodology. The twin model only incorporate twins, and they 
are born the same day and are assumed to share their childhood 
environment. However, this is not the case in siblings that can be born many 
years apart. Our sibling model handled this and other differences by 
Model Cut-off
Observed 
Outcome 
Occurrence
Additive 
Genetic 
(A)
Shared 
(C) 
Non-
shared (E)
Monozygotic 
Twins
Dizygotic 
Twins
0.49 NA 0.51 0.51 0.19
(0.34-0.63) (0.37-0.66) (0.08) (0.10)
0.54 NA 0.46 0.59 0.11
(0.38-0.69) (0.31-0.62) (0.08) (0.12)
0.54 NA 0.46 0.55 0.22
(0.35-0.70) (0.31-0.65) (0.09) (0.14)
0.53 NA 0.47 0.54 0.29
(0.32-0.70) (0.30-0.68) (0.10) (0.16)
0.51 NA 0.49 0.53 0.15
(0.20-0.74) (0.26-0.80) (0.14) (0.23)
NA NA NA 0.56 Nac
(0.18)
c No concordant dizygotic twins.
AEb ≥8 13.6%
5.2%
AEb ≥16 3.3%
AEb ≥18 1.6%
b An AE model, were the C parameter was fixed at zero, was considered as the estimate of C was statistically 
insignificant in the ACE model.
 Table 5.3. Univariate heritability estimates of perinatal depression with different Edinburgh Postnatal
 Depression Scale cut-offs using classical twin design (N=3,427)*
Abbreviations: CI, confidence interval. SE, standard error. NA, not applicable.
* Different cut-offs on the Edinburgh Postnatal Depression Scale was used to define a binary outcome 
variable of perinatal depression. A score of ≥12 is the widely used cut-off to define a depressive illness.
7.6%
Environment
Estimated Variance
(95% CI)
Tetrachoric Correlation
(SE)
10.6%AEb
AEb ≥12
≥10
AEb ≥14
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adjusting the prevalences for whether the family included half-siblings, as 
well as for birth year (both linear and squared) and non-perinatal depression 
was additionally adjusted for time at risk (linear and squared) and perinatal 
depression for number of offspring. The register based methodology for 
detection may have a lower precision, which may decrease the overall 
heritability estimates, which could further explain why non-perinatal 
depression also was estimated lower in our study than in previous studies.51 
Another novel finding from this study was that perinatal depression and non-
perinatal depression have partially different genetic etiologies. One third of 
the genetic variance in perinatal depression was unique for the type of 
depression, and not seen in non-perinatal depression. In line with the 
previous discussion, this may be affected by potential miss-classification and 
could be larger if an exact definition of perinatal depression and non-
perinatal depression existed. This difference is interesting and important, as 
it suggest that within the current heterogeneous definition of depression, 
there are potentially distinctive sub-types. It is, however, important to note 
that this is a quantitative genetic approach that and cannot distinguish the 
exact genes and corresponding functional biology. It is possible that this 
unique genetic portion is related to the female specific fluctuations during 
pregnancy and childbirth, but this has to be explored further. 
Moreover, when separating depressive illness into perinatal depression and 
non-perinatal depression, we only permit perinatal depression to occur 
during perinatal periods whereas non-perinatal depression can occur at any 
time of life (excluding perinatal periods). Pregnancy tends to be clustered 
around a specific age in women, and this generates a possibility that the 
discrepancy observed between perinatal depression and non-perinatal 
depression could be caused by a factor related to the different ages when 
depression was experienced, rather than by the actual pregnancy or 
childbirth. One way to study this is through permutation where women born 
the same year are randomly assigned each other's perinatal periods. For 
example, woman 1, born 1955, has been pregnant two times: the first time at 
age 27 and the second at age 32. After permutation, she has randomly been 
assigned the perinatal periods of woman 2. Woman 2 is also born 1955 but 
has been pregnant three times, at age 24, 29 and 36. This gives woman 1 
three perinatal periods originally belonging to woman 2, and none of these 
overlap with her original perinatal periods. However, they are still within the 
age range where most women born that year get pregnant. See Figure 4.3 for 
a graphical representation of the permutation procedure. 
Applying this permutation approach assigned 84.4% of the women in the 
cohort to permuted periods that did not overlap with their own real perinatal 
periods. Using these permuted periods, depressive illness was then separated 
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into perinatal depression and non-perinatal depression just like before. 
However, this time perinatal depression would not actually denote 
depression in a perinatal period in 84.4% of the women, but rather a non-
perinatal period at the same age range where most women born that year 
would be pregnant. Bivariate analysis revealed that the variance in the 
permuted perinatal depression was explained completely by genetic factors 
in common with non-perinatal depression, without any genetic factors 
unique for the permuted perinatal depression. In other words, when 
perinatal depression was defined as depression around the "childbearing 
age", but not during the real perinatal periods, no unique genetic component 
was observed. This lends support to an association between the unique 
genetic component originally observed in perinatal depression and the actual 
pregnancy or childbirth. 
We further tested if the unique additive genetics seen in perinatal depression 
was explained by bipolar disorder or schizophrenia. However, excluding all 
individuals in the sibling design with at least one hospital admission with a 
discharge diagnosis code for bipolar disorder or schizophrenia (N=6,817) did 
not alter the results. 
Overall, the results from this study may provide clinicians with important 
information that will assist counseling patients regarding the prognosis and 
risk of perinatal mood disorders. The heritability of a disorder can have a 
direct translational impact in dialogues between treating clinicians and 
patients. Patients commonly ask questions as to “why am I affected by 
perinatal depression?”, “is it my fault?”, “will it happen the next time?”. The 
results underline the need for clinicians to obtain detailed information 
concerning the patient’s personal and family history of mental illness that 
started during the perinatal period. Integration of genetic risks with 
environmental factors is central for the proper tailoring of individual 
treatment and discussions of prognosis. 
Moreover, perinatal depression may represent a form of unipolar mood 
disorder that could be prioritized for genomic discovery efforts. Adequately 
powered studies of perinatal depression could provide genomic findings 
important to disentangling the disorder specific etiology and potential 
relevance to depressive illness in general. Finally, enhanced identification of 
women at risk for perinatal depression could result in targeted interventions 
to prevent, identify, and treat perinatal depression. 
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5.5 STUDY III RESULTS 
5.5.1 FULL POPULATION SAMPLE 
Using information from the Swedish Medical Birth Register, we were able to 
identify 392,029 children born between April 1st 2006 and December 31st 
2009. Among these children, 6,572 (1.7%) had a mother with several 
dispensations of an SSRI, while 1,625 (0.4%) of the children had a mother 
with a treatment contact for depression during pregnancy, but no SSRI 
medication. 
 
 
 
Comparing children between different groups revealed children prenatally 
exposed to SSRIs having lower birth length and smaller birth head 
circumference, shorter gestational age at birth, and a higher probability of 
preterm birth. See Table 5.6. 
5.5.2 WITHIN-FAMILY SAMPLE 
From the full population sample, we identified 1,007 full siblings from 496 
families where the siblings were discordant for SSRI exposure. 
Reference 
Group
SSRI 
Exposed
Depression 
Without SSRI 
Exposed Total
383,832 (97.9) 6,572 (1.7) 1,625 (0.4) 392,029
Compulsory school 10.8 15.8 25.0 11.0
Upper secondary school 39.8 42.9 45.4 39.9
Post secondary education less 
than 3 years 12.4 12.2 9.9 12.4
University 3 years or more 36.9 29.2 19.7 36.7
BMI 24.6 (4.5) 25.6 (5.2) 25.4 (5.1) 24.6 (4.5)
Height (cm) 166.4 (6.4) 166.8 (6.2) 165.7 (6.5) 166.4 (6.4)
Age at pregnancy 30.3 (5.2) 31.0 (5.4) 30.0 (5.8) 30.4 (5.3)
Elective 7.3 10.4 10.7 7.3
Acute 9.2 12.3 11 9.3
7.7 52.1 64.9 8.7
Does not smoke 93.2 84.9 80.1 93.0
1-9 cigarettes / day 5.3 10.5 13.4 5.4
>9 cigarettes / day 1.5 4.6 6.4 1.6
Abbreviations: SSRI, selective serotonin reuptake inhibitor. BMI, body mass index (weight in kilograms 
divided by height in meters squared).
 Table 5.4. Descriptive characteristics of the full population sample
Mother characteristics, mean (SD)
Mother's education, %
Characteristic
Number of children (%)
Caesarean section, %
Previous psychiatric history, %
Smoking, first visit at maternal 
care, %
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The associations between SSRI exposure and birth length, birth head 
circumference, and birth weight observed in the full cohort were all 
diminished in the within-family analyses. Gestational age at delivery was 
lower (-2.27 days; 95% CI -3.79 to -0.75; P=0.004) in the SSRI exposed 
group of children, and the odds ratio for preterm birth was similar as in the 
population cohort, although with confidence intervals overlapping zero. See 
Table 5.6. 
This remaining difference may be due to the depression underlying the 
medication. Therefore we compared children exposed to depression (without 
prenatal SSRI exposure) with children of mothers without either a diagnosis 
of depression or SSRI medication. These children had also lower gestational 
age (-1.69; 95% CI -2.51 to -0.86; P<0.001) and higher probability of preterm 
birth (odds ratio 1.31; 95% CI 1.07 to 1.60; P=0.009). See Table 5.6. 
N % N %
506 50.3 501 49.7
First 315 63.5 181 36.5
Second 185 37.3 311 62.7
Third 5 35.7 9 64.3
Fouth 1 100 0 0
First 198 59.1 137 40.1
Second 210 49.0 219 51.0
Third 55 39.6 84 60.4
Fourth 21 36.2 37 63.8
Fifth 11 42.3 15 57.7
Sixth 8 80.0 2 20.0
Seventh 1 20.0 4 80.0
Eighth 1 33.3 2 66.7
Ninth 1 50.0 1 50.0
Elective 32 6.3 37 7.4
Acute 44 8.7 46 9.2
Abbreviations: SSRI, selective serotonin reuptake inhibitor. 
Reference 
Group
SSRI Exposure 
Group
 Table 5.5.  Descriptive characteristics of the within-family sub-sample
Parity
Caesarean section
Birth order among included siblings
Characteristic
Number of children
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5.6 STUDY III DISCUSSION 
In this study, we initially observed associations between prenatal SSRI 
exposure and a number of birth size related outcomes, similar to previous 
studies.138,142,145 However, this was when a classic epidemiologic approach 
was used that adjusted for several measured confounding factors, but not for 
potential unmeasured familial confounding. When a within-family approach 
was used where full siblings with discordant SSRI exposure were compared, 
the associations between SSRI exposure and birth size related outcomes were 
no longer observed. This could suggest that the associations between SSRI 
exposure and birth size outcomes initially observed was due to unmeasured 
familial confounding, i.e. parents genetics or environmental exposures 
preceding the pregnancies, which the measured confounding factors could 
not properly adjust for. In other words, the children exposed to SSRIs during 
gestation in the initial analysis had indeed impaired growth, but the within-
family approach demonstrated that there were no difference between an 
exposed and an unexposed sibling, suggesting that the impaired growth was 
due to other underlying genetic or environmental factors shared by the 
siblings. 
Coefficient 95% CI Coefficient 95% CI
SSRI Exposure -.14 -.16 to -.11 .01 -.1 to .11
Depression without SSRI exposure .06 .01 to .11 NA NA
SSRI Exposure -.08 -.10 to -.05 -.03 -.14 to .08
Depression without SSRI exposure .05 -.01 to .10 NA NA
SSRI Exposure -.01 -.04 to .02 .05 -.05 to .14
Depression without SSRI exposure .03 -.026 to .01 NA NA
SSRI Exposure -3.12 -3.53 to -2.70 -2.27 -3.79 to -.75
Depression without SSRI exposure -1.69 -2.51 to -.86 NA NA
SSRI Exposure 1.45 1.31 to 1.61 1.36 .77 to 2.42
Depression without SSRI exposure 1.31 1.07 to 1.60 NA NA
a The population analyses were adjusted for the mother's education, the mother's BMI  (<18.5, 18.5-25, 25-
30, >30), the mother's height (cm), parity, the mother's age at pregnancy (years), the mother's previous 
psychiatric history (yes/no), the mother's smoking at first visit to maternal care (1: no smoking. 2: 1-9 
cigarettes/day. 3: >9 cigarettes / day). The population analyses used robust standard errors to account for 
several children from the same mother. The within-family analyses were adjusted for parity.
b The outcome variable is a standardized value adjusted for gestational age (see Methods). Standardized 
values for birth weight, birth length, and birth head circumference above or below five standard deviations 
from the sample mean (N=465)  were considered outliers and excluded from the analyses.
Abbreviations: SSRI, selective serotonin reuptake inhibitor. CI, confidence interval. NA, not applicable.
 Table 5.6. Results from study III
Characteristic
Birth Lengtha,b
Preterm Birtha
Population analysis 
(N=392,029)
Within-family analysis 
(N=1,007)
Birth Head Circumferencea,b
Birth Weighta,b
Gestational Age at Deliverya
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On the contrary, a shorter gestational age was observed both when using the 
classic epidemiological approach, and when using the within-family 
approach. Although there have been no family or sibling studies of prenatal 
SSRI exposure and gestational age, our results are in line with those of 
studies using a classic epidemiological approach.136,138,142 The estimate size of 
this association was 3.1 fewer days of gestation in the classical approach, and 
2.3 fewer days in the within-family approach. This finding is interesting and 
could have several conceivable explanations. Firstly, the association may 
denote a causal effect of the SSRI on gestational age. Another explanation 
may be that the underlying disorder, depression, leading up to the 
antidepressant treatment is causing the association. A third possibility would 
be that the association is due to the liability underlying both the depression 
and the consequent antidepressant treatment.  
To test these potential explanations, we contrasted women having at least 
one treatment contact with a discharge diagnosis code for depression but no 
SSRI medication during pregnancy, with women not having a treatment 
contact for depression or SSRI medication during pregnancy. The analyses 
showed that women with a depression diagnosis only were more likely to 
have both shorter gestational age and preterm birth offspring compared with 
women without a healthcare contact for depression or a SSRI medication 
during pregnancy. If the liability for depression were the only influence on 
gestational age, the association would likely be attenuated in the within-
family analyses, as both siblings have the same parents. However, an 
association was seen, indicating influence from factors other than the 
liability, for example the medication, or the depression leading to the 
medication. 
To continue discuss these results, it is important to remember that the birth 
size outcomes in this study were standardized based on gestational age. This 
is, as previously mentioned, because time in gestation is strongly correlated 
with the size at birth - a child allowed less time to grow will correspondingly 
be born smaller.227 Without this standardization, it would be difficult to 
survey deviation in growth, and whether a potential association was targeting 
the growth, or just shorter gestational time that produces a child that has 
been allowed less time to grow and consequently are smaller. See Figure 5.6 
below.  
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In the within-family model, the SSRI exposed child has on average 2.3 fewer 
days in gestation compared to the unexposed sibling. However, neither the 
exposed, nor the unexposed child display any changes in gestational age 
adjusted size outcomes. In other words, the SSRI exposed child has shorter 
time in gestation, which in turn reduces the birth size, but it does not seem to 
cause growth impairment. This in turn could be due to both siblings not 
deviating from the growth curve, or that both siblings deviate in similar ways. 
Another aspect is the growth during gestation and the shape of normal intra-
uterine growth curves. The curves displays sigmoidal shapes that commonly 
starts plateau at around week 38. After this, there is less pronounced growth, 
and if both siblings are born after week 38, the 2.3 fewer days of gestation 
potentially caused by the SSRI exposure may not produce pronounced 
differences in size between the exposed and unexposed sibling. 
Alternately, the observed shorter time of gestation in the SSRI exposed child 
could be fully or partially due to other types of confounding. The within 
family analysis does not adjust for changes in behavior as a consequence of 
perceived consequences of exposure. That might be the case if a first 
pregnancy is exposed, and the child is born with a certain outcome due to 
causes other than the exposure, and this outcome of the first child in turn 
results in changes in both exposure and relevant behavior associated with the 
real cause. This could result in a within-family association between an 
9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41
Weeks
* This curve represents the intra-uterine growth of a child during pregnancy. In this figure, A represents a 
child born with a normal gestational age, and with a normal size for that age. B on the other hand is smaller, 
but this is likely due to being born earlier and consequently not having been allowed equal amount of time to 
grow as A, rather than having impaired growth. Both A and B follow the intra-uterine growth curve, and with 
birth size outcomes standardized for gestational age, a comparison of B and A would not reveal a difference, 
as they both are within the size expected for their gestational age. On the contrary, C has the same 
gestational age as B, but is also smaller than what is expected. Therefor, a comparison between C and A 
would reveal a difference and would indicate impaired growth of C.
Size
Figure 5.6. Intra-uterine growth curve example*
A 
B 
C
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exposure and an outcome, which may in reality be affected by another 
underlying factor. This is sometimes called a carry over effect, and it has been 
shown very complicated to adjust for.180  
Another potential explanation would be if an association between an 
exposure, e.g. SSRI medication, and an outcome, e.g. shorter gestation, were 
confounded by a factor that is unshared between the siblings, e.g. an 
automobile accident (assuming that this automobile accident is not due to a 
trait underlined by genetics like attention deficit,228,229 but rather unrelated 
in a type of a-piece-of-a-passing-airplane-suddenly-falls-into-the-road way). 
In the within-family model, only siblings that are discordant for the exposure 
are informative. If we assume that automobile accidents are associated with 
depression and thereby SSRI medication, and also that that automobile 
accidents cause some sort of reaction that reduces the time of gestation. Then 
the other sibling, which will not be exposed to an SSRI medication due to the 
study design, will also be less likely to have been exposed to a mother in an 
automobile accident during pregnancy (due to this made-up correlation 
between automobile accidents and SSRI medication), and consequently the 
automobile accident-specific reduction of gestation time would not affect this 
sibling. 
In the end, whether to use a within-family design or not becomes a balance 
between potential gains from controlling for unmeasured shared 
confounding like genetics and parental environmental factors, and potential 
problems caused by unshared confounders. If unshared confounding is 
assumed a major problem for the studied exposure and outcome, a within-
family design may not be suitable. However, based on previous literature on 
psychiatric genetics,8,9,16,21,175-177 and the results from Study II,230 we assume 
that depression around the time of pregnancy is a trait with considerable 
influence by genetics. We therefore consider the studied variables well suited 
for the within-family design. As such, we conclude that these study results 
indicate that prenatal SSRI exposure may not be causally related to offspring 
birth size. Rather, our analyses imply that the associations between prenatal 
SSRI exposure and the studied birth size outcomes may be due to other 
underlying factors that are adjusted for in a within-family analysis.  
Depression is considered a complex and highly polygenic trait, much like 
most other psychiatric disorders studied with genome-wide association 
studies.16,25 Growth is also a complex polygenic trait,231,232 and it is not 
unthinkable that shared additive genetics exists behind psychiatric disorders 
and outcomes related to growth, such as birth size. Further, runs of 
homozygosity have been associated both to reduced height and to complex 
disorders such as Alzheimer’s disease and schizophrenia,233,234 and may serve 
as a common causal pathway to both depression and reduced growth. 
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Although the study did find an association between maternal SSRI 
medication and shorter gestation, this reduction of gestational age was minor 
and could either be due to the exposure of the antidepressant, or due to 
factors varying between the pregnancies. While the study cannot rule out a 
causal effect of SSRI medication on shortened gestational age, the association 
was reduced between the classical epidemiological approach and the within-
family approach, and the associations to the birth size related outcomes were 
attenuated. This is important, as it could indicate that many of the numerous 
reported associations between antidepressant treatment during pregnancy 
and outcomes in the offspring, several which fail replication, may be due to 
factors other than the medication. 
 
5.7 STUDY IV RESULTS 
In total, from 1973 through 2009, we identified 1,857,043 mothers giving 
birth to 3,637,895 children, and 1,835,602 fathers to 3,589,251 children 
(98.7%). Using data from this cohort, we created a sub-sample of parents 
living in Stockholm County having at least one child between the beginning 
of 2004 and the end of 2009. This included 101,671 mothers and 92,974 
fathers. 
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In the nation-wide cohort we observed perinatal depressive illness among 
10,465 mothers (0.56%), perinatal anxiety disorders among 8,946 mothers 
(0.48%), and 3,633 mothers having both disorders. Among the fathers, 4,864 
(0.26%) had perinatal depressive illness, 4,379 (0.24%) had a perinatal 
anxiety disorder, and 1,189 of the fathers had both. See Table 5.8. In the 
Stockholm County sub-sample, a majority of the diagnoses came from 
primary care and only 13-16% of the diagnosed parents had been in contact 
with both primary and specialist care. See Table 5.9. In this sub-sample, 
1,956 mothers (1.92%) had perinatal depressive illness, 1,490 (1.47%) had a 
perinatal anxiety disorder, and 475 mothers had both disorders. Among the 
fathers, we observed 1,267 (1.36%) with perinatal depressive illness, 914 
(0.98%) with a perinatal anxiety disorder, and 256 with both disorders. See 
Table 5.9. 
No 
Perinatal 
Depressive 
Illness
Perinatal 
Depressive 
Illness
No 
Perinatal 
Depressive 
Illness
Perinatal 
Depressive 
Illness
No 
Perinatal 
Depressive 
Illness
Perinatal 
Depressive 
Illness
No 
Perinatal 
Depressive 
Illness
Perinatal 
Depressive 
Illness
3,626,766 
(99.7%)
11,129 
(0.3%)
3,584,066 
(99.9%)
5,185 
(0.1%)
135,050
(96.6%)
4,809 
(3.4%)
125,428 
(97.7%)
2,958 
(2.3%)
- 24 23.7 18.7 9.4 9.4 8.4 8.7 2.6 3.0
25 - 34 63.0 59.1 61.2 48.4 62.8 58.3 47.3 44.5
34 - 13.3 22.1 29.4 42.2 28.8 32.9 50.0 52.5
23.6 (4.1) 25.1 (5.0) 23.6 (4.1) 24.8 (5.0) 23.9 (4.1) 24.5 (4.6) 23.8 (4.1) 24.4 (4.5)
Does not 
smoke 82.0 78.8 82.06 77.37 94.6 89.1 94.9 91.8
1-9 cigarettes 
/ day 12.0 13.1 11.54 14.82 4.1 7.9 3.9 5.9
>9 cigarettes / 
day 6.5 8.1 6.41 7.81 1.3 3.1 1.2 2.3
Acute 2.2 8.1 2.2 6.6 10.9 13.5 10.7 12.1
Planned 1.9 8.1 1.9 5.1 9.8 12.7 10.0 11.5
6.1 9.6 5.8 7.0 5.7 7.8 5.6 6.5
First 42.0 43.5 51.2 44.9 43.3 40.8 43.8 38.3
Second 36.6 31.8 33.2 31.0 38.2 35.8 37.5 37.7
Third 15.1 15.3 11.5 14.9 13.7 15.7 13.4 16.1
Fourth and up 6.3 9.4 4.1 9.2 4.8 7.7 5.3 7.9
b Exact parity information is not available for the fathers. Here, parity represents the order or births within the Medical 
Birth Register. Births prior to 1973, or among the 1 % not in the register, will not be included.
Abbreviations: SD,Standard deviation.
a Numbers are rounded to one decimal
Characteristica
Mothers 
N = 1,857,043
Fathers 
N = 1,835,602
Mothers 
N = 101,671
Fathers 
N = 92,974
 Table 5.7.  Descriptive statistics of the nation-wide cohort and the Stockholm County sub-sample
Age at pregnancy, 
%
Mean BMI of 
mother (SD)
Parityb
Number of 
perinatal periods
Mother's 
smoking, first 
visit at maternal 
care, %
Caesarean section 
of mother, %
Preterm birth, %
Nation-wide cohort 
1973-2009
Stockholm County sub-sample
2004-2009
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Parent Disoder N 
parent 
N 
children
Occurrence (%)
perinatal periods 
Differenceb Occurrence (%)
permuted periods
Overlapping  
periodsc
Mean days 
between 
(SD)d 
Depression 1,857,043 3,637,895 10,465 (0.56) -21,8% *** 13,381 (0.72) 29.7 % 1,975 (1,564)
Anxiety 1,857,043 3,637,895 8,946 (0.48) -18,8% *** 11,023 (0.59) 29.7 % 1,975 (1,564)
Depression & anxiety 1,857,043 3,637,895 15,778 (0.85) -14,7% *** 18,505 (1.00) 29.7 % 1,975 (1,564)
Depression 1,835,602 3,589,251 4,864 (0.26) -33,6% *** 7,326 (0.40) 27.8 % 2,183 (1,797)
Anxiety 1,835,602 3,589,251 4,379 (0.24) -23,5% *** 5,723 (0.31) 27.8 % 2,183 (1,797)
Depression & anxiety 1,835,602 3,589,251 8,054 (0.44) -28,0% *** 11,193 (0.61) 27.8 % 2,183 (1,797)
 Table 5.8.  Nation-wide occurrence of depression and anxiety disorders during perinatal periods and during permuted periodsa
b The difference in occurrence during the perinatal periods compard with the permuted periods expressed as percentualdifference. I.e. the 
occurrence during perinatal periods divided by the occurrence during the permuted periods.The differences in occurrence between the 
studied periods were analyzed using chi-squared tests, and the resulting p-values are given with each percentual change as follows: ns (non-
significant) denotes P > 0.05, * denotes P ≤ 0.05, ** denotes P ≤ 0.01, and *** denotes P ≤ 0.001.
c The percent of permuted periods that completely or partially overlap with a parents real perinatal period. A higher figure will cause the 
difference between permuted and perinatal periods to be less prononced.
d The mean number of days between permuted periods and the real perinatal periods. E.g. a number of 365 would indicate that, on 
average, a permuted period covers a time window a year prior or after the perinatal period.
Mother
Father
a The percentual occurrences are based on the number of parents.
Parent Disoder N 
parent 
N 
children
Occurrence 
(%)
perinatal 
period 
Differenceb Occurrence 
(%)
permuted 
period
Overlapping  
periodsc
Mean days 
between 
(SD)d
Depression 101,671 139,859 1,956 (1.92) -29,6% *** 2,780 (2.73) 50.1 % 734 (536)
Anxiety 101,671 139,859 1,490 (1.47) -31,7% *** 2,181 (2.15) 50.1 % 734 (536)
Depression & anxiety 101,671 139,859 2,971 (2.92) -30,7% *** 4,289 (4.22) 50.1 % 734 (536)
Depression 92,974 128,386 1,267 (1.36) -12,6% *** 1,449 (1.56) 50.0 % 738 (535)
Anxiety 92,974 128,386 914 (0.98) -11,4% ** 1,032 (1.11) 50.0 % 738 (535)
Depression & anxiety 92,974 128,386 1,925 (2.07) -12,3% *** 2,195 (2.36) 50.0 % 738 (535)
Parent Disoder Occurrence 
(%)
specialist 
care 
Differencef
specialist 
care
Occurrence 
(%)
permuted
specialist care 
Occurrence 
(%)
primary care 
Differenceg
primary care
Occurrence 
(%)
permuted 
primary care 
Overlaph 
(%)
 specialist 
and primary 
care
Depression 937 (0.92) -1,1% ns 947 (0.93) 1,296 (1.27) -42,1% *** 2,237 (2.20) 277 (14.2)
Anxiety 794 (0.78) 0,5% ns 790 (0.78) 931 (0.92) -46,5% *** 1,741 (1.71) 235 (15.8)
Depression & anxiety 1,388 (1.37) 1,1% ns 1,373 (1.35) 2,046 (2.01) -42,5% *** 3,557 (3.50) 463 (15.6)
Depression 513 (0.55) -12,6% * 587 (0.63) 932 (1.00) -11,2% ** 1,050 (1.13) 178 (14.0)
Anxiety 293 (0.32) -10,4% ns 327 (0.35) 756 (0.81) -10,6% * 846 (0.91) 135 (14.8)
Depression & anxiety 669 (0.72) -12,7% * 766 (0.82) 1,512 (1.63) -11,4% *** 1,707 (1.84) 256 (13.3)
h The number of perinatal periods where a subject received both specialist and primary healthcare.
Mother
Father
Mother
Father
a The differences in occurrence between the studied periods were analyzed by chi-squared tests, and the resulting p-values are given with 
each percentual change as follows: ns (non-significant) denotes P > 0.05, * denotes P ≤ 0.05, ** denotes P ≤ 0.01, and *** denotes P ≤ 
0.001. The percentual occurrences are based on the number of parents.
B: Specialist care and primary care separatede
 Table 5.9. Occurrence of depression and anxiety disorders during perinatal periods and permuted periods in the Stockholm County sub-
 samplea
b The percentual difference in occurrence between the permuted period and the perinatal period. I.e. the occurrence during perinatal 
period divided by the occurrence during the permuted period. Including data from both specialist care and primary care.
f The percentual difference in occurrence between the permuted period and the perinatal period. I.e. the occurrence during perinatal 
period divided by the occurrence during the permuted period. Including data from specialist care only.
g The percentual difference in occurrence between the permuted period and the perinatal period. I.e. the occurrence during perinatal 
period divided by the occurrence during the permuted period. Including data from primary care only.
c The percent of permuted periods that completely or partially overlap with a parents real perinatal period. A higher figure will cause the 
difference between permuted and perinatal periods to be less prononced.
d The mean number of days between permuted periods and the real perinatal periods. E.g. a number of 365 would indicate that, on 
average, a permuted period covers a time window a year prior or after the perinatal period.
e The (B) table with specialist care and primary care is based on the same number of parents and children, the same portion of overlapping 
periods, and the same mean days between perinatal and permuted periods, as reported in (A).
A: Specialist care and primary care combined
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When the pregnancy was compared to adjacent periods, a lower occurrence 
of depression, and anxiety disorders, were observed among the mothers 
compared both to the period prior and after pregnancy. The largest 
occurrence was observed in the postnatal period. See table 5.10. A similar 
pattern was observed for depression among the fathers in the nation-wide 
cohort with lower occurrence during pregnancy than both prior conception 
and after childbirth. However, the occurrence of depression in the Stockholm 
County cohort, and the occurrence of anxiety disorders in both cohorts, 
displayed a step-wise pattern with the lowest occurrence prior conception 
and highest after childbirth. See Table 5.10. When the whole perinatal period 
were compared to periods of equal length (i.e. roughly 15 months) prior 
conception, and after six months postpartum, lower occurrence prior 
conception and higher occurrence in the period following the perinatal 
period were observed among both mothers and fathers, but with higher 
estimates among the fathers in the nation-wide cohort than among the 
mothers. See Table 5.10. 
After permutation, 28-30% of the permuted periods overlapped with original 
perinatal periods in the nation-wide cohort. The occurrence in the perinatal 
periods compared to the permuted periods were 21.8% lower for depression, 
and 18.8% lower for anxiety disorders among the mothers. See Table 5.8. The 
occurrence of diagnoses for fathers in the perinatal periods compared to the 
permuted periods were 33.6% lower for depression, and 23.5% lower for 
anxiety disorders. See Table 5.8. After permutation of the Stockholm County 
sub-sample, 50% of the permuted periods overlapped with perinatal periods. 
In this sub-sample, the occurrence in the perinatal periods compared to the 
permuted periods was 29.6% lower for depression, and 31.7% lower for 
anxiety disorders among the mothers, with limited contribution to the 
difference from specialist care, but major contribution from primary care. 
See Table 5.9. The occurrence among the fathers in the perinatal periods 
compared to the permuted periods were 11.4% lower for depression, and 
12.3% lower for anxiety disorders, with equal contribution to the difference 
from both specialist care and primary care. See Table 5.9. 
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Parent Disorder Cohort N 
parent 
N 
children
Occurrence 
(%) 
before 
Differenceb Occurrence 
(%)  
pregnancy 
Differencec Occurrence 
(%) 
after  
Nation-wide 1,709,101 3,107,949 5,506 (0.18) -13,5% *** 4,761 (0.15) -30,8% *** 6,879 (0.22)
Stockholm County 64,180 71,748 1,298 (1.81) -12,8% *** 1,132 (1.58) -27,2% *** 1,554 (2.17)
Nation-wide 1,709,101 3,107,949 4,431 (0.14) -1,4% ns 4,367 (0.14) -20,6% *** 5,501 (0.18)
Stockholm County 64,180 71,748 774 (1.08) -18,5% *** 631 (0.88) -19,5% *** 784 (1.09)
Nation-wide 1,692,289 3,074,292 2,755 (0.09) -9,2% *** 2,501 (0.08) -24,3% *** 3,303 (0.11)
Stockholm County 58,663 65,779 514 (0.78) 8,6% ns 558 (0.85) -22,6% *** 721 (1.10)
Nation-wide 1,692,289 3,074,292 2,202 (0.07) 5,3% * 2,319 (0.08) -16,4% *** 2,775 (0.09)
Stockholm County 58,664 65,780 352 (0.54) 17,6% ** 414 (0.63) -13,6% ** 479 (0.73)
Parent Disorder Cohort N 
parent 
N 
children
Occurrence 
(%) 
before 
Differenced    Occurrence 
(%)  
perinatal 
period 
Differencee Occurrence 
(%) 
after  
Nation-wide 1,319,000 2,010,523 5,164 (0.26) 9,6% *** 5,661 (0.28) -9,2% *** 6,237 (0.31)
Stockholm County 28,289 28,288 759 (2.68) 12,3% ** 852 (3.01) -24,3% *** 1,125 (3.98)
Nation-wide 1,319,000 2,010,523 4,059 (0.20) 21,6% *** 4,937 (0.25) -3,6% * 5,122 (0.25)
Stockholm County 28,289 28,288 441 (1.56) 1,4% ns 447 (1.58) -30,0% *** 639 (2.26)
Nation-wide 1,311,076 1,990,515 2,668 (0.13) -4,0% ns 2,561 (0.13) -38,3% *** 4,153 (0.21)
Stockholm County 26,026 26,027 286 (1.10) 37,1% *** 392 (1.51) -26,2% *** 531 (2.04)
Nation-wide 1,311,076 1,990,515 2,021 (0.10) 12,4% *** 2,271 (0.11) -27,0% *** 3,111 (0.16)
Stockholm County 26,026 26,027 203 (0.78) 37,4% *** 279 (1.07) -11,7% ns 316 (1.21)
 Table 5.10. Occurrence of depression and anxiety disorders during the pregnancy and adjacent periods (A), and during the perinatal 
 period and adjacent periods (B)a
e The percentual difference in occurrence during the perinatal period compared to the before-period. I.e. the occurrence during perinatal 
period divided by the occurrence during the before-period.
e The percentual difference in occurrence during the perinatal period compared to the after-period. I.e. the occurrence during perinatal 
period divided by the occurrence during the after-period.
B: PERINATAL PERIOD
A: PREGNANCY
a The adjacent periods are of same length as the period compared. For A, that is a period prior conception of equal length to the pregnancy, 
and a period after childbirth of equal length to the pregnancy. For B, that is a period prior conception of equal length to the perinatal period 
(pregnancy and six months postpartum), and a period after six months postpartum of equal length to the perinatal period (pregnancy and six 
months postpartum). For example, assuming a pregnancy of exactly nine months, A compares the nine months of pregnancy to nine months 
prior, and nine months after, and B compares a fifteen month perinatal period to fifteen months prior conception, and fifteen months after 
the perinatal period. The differences in occurrence between the studied periods were analyzed by logistic regression using robust standard 
errors clustered on the parent, and the resulting p-values are given with each percentual change as follows: ns (non-significant) denotes P > 
0.05, * denotes P ≤ 0.05, ** denotes P ≤ 0.01, and *** denotes P ≤ 0.001. The percentual occurrences are based on the number of children 
(pregnancies).
b The percentual difference in occurrence during the pregnancy compared to the before-period. I.e. the occurrence during pregnancy divided 
by the occurrence during the before-period.
e The percentual difference in occurrence during the pregnancy compared to the after-period. I.e. the occurrence during pregnancy divided 
by the occurrence during the after-period.
Mother
Depression
Anxiety
Father
Depression
Anxiety
Mother
Father
Depression
Anxiety
Depression
Anxiety
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5.8 STUDY IV DISCUSSION 
With this study, we surveyed healthcare utilization data among 3.6 million 
parents of 3.5 million children in Sweden. Perinatal depression based on 
specialist healthcare was found uncommon, 0.56% among mothers 0.26% 
among fathers. However, in a sub-sample of parents living in Stockholm 
County during more recent years, we could also monitor primary healthcare, 
and estimated the occurrence of perinatal depression at 1.92% among 
mothers, and at 1.36% among fathers. Addition of a broad definition of 
anxiety disorders onto the perinatal depression further resulted in an 
increased estimated occurrence at 2.92% among mothers, and at 2.07% 
among fathers. This is still far from the estimates reported from studies using 
a self-report instruments,58-60,230,235 and may indicate that anxiety disorders 
does not explain the discrepancy in estimated occurrence between 
occurrence figures based on self-report and treatment data. However, as 
opposed to the previous self-report estimates that survey lifetime occurrence, 
the Stockholm County cohort did only cover a limited number of years and it 
is possible that the figure would be larger if all lifetime pregnancies would be 
surveyed. Yet, it is unlikely that the figure would reach 10-15%.  The observed 
occurrence is, however, in line with reports from studies using similar data 
from other countries, including the US and Finland,73,80,81 showing the low 
occurrence of treatment for depression and anxiety disorders around the 
time of pregnancy is not an issue specific for Sweden. 
When we compared the pregnancy with adjacent periods, the mothers 
displayed a pattern of reduced occurrence of both depression and anxiety 
disorders during pregnancy, and overall highest occurrence after pregnancy. 
This is in line with findings from earlier studies73,93,236 The fathers also 
displayed the highest occurrence after pregnancy, but had more of a step-
wise pattern with lower occurrence prior pregnancy, except for depression 
identified with specialist data only, that displayed a lower occurrence 
specifically during pregnancy. An interpretation of these patterns could be 
that the number of diagnosed individuals generally increases over time, 
which may be what is seen in the fathers. In contrast, this pattern is not seen 
among the mothers, where instead the occurrence is reduced during the 
pregnancy. 
We similarly compared the whole perinatal period with adjacent periods of 
same length. See Figure 4.2. This meant that we now compared the 
occurrence during both pregnancy and a postnatal period, and this postnatal 
period had shown having the highest occurrence in the previous 
comparisons. Therefore, the observation of higher occurrence during the 
perinatal period compared to an equally long period before may be expected. 
This was consistent for both fathers and mothers, and we further observed a 
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higher occurrence in the period following the perinatal period. However, 
when using adjacent periods it is difficult to interpret if this observed 
stepwise increase denotes an increase in occurrence that can be attributable 
to the pregnancy and childbirth, or if this signifies a secular pattern of 
increased diagnoses over time. 
The permutation approach allowed us to better understand the patterns of 
occurrence during the perinatal period through comparisons of periods of 
equal length prior or after the perinatal period within the same individual, 
without influence from fixed calendar time as the periods were scattered both 
prior and after the original perinatal period. Through being based on the 
perinatal periods from another individual born the same year, the permuted 
periods was distributed to represent the time of life when individuals born 
the same year would have children, thereby allowing relevant periods of life 
to be compared. The random distribution of the permuted periods did, 
however, result in some overlap between permuted periods and the 
individual’s actual perinatal periods. This was true for about 30% of the 3.6 
million perinatal periods in the nation-wide cohort, consequently causing 
about 30% of the permuted periods to entirely, or partially, cover a real 
perinatal period. This would in turn result in permuted periods that actually 
represent the perinatal period, and thus a conservative estimate of the 
difference. Nevertheless, when we applied this approach on the nation-wide 
cohort with specialist care data, we observed 22% lower occurrence of 
treatment for depressive illness among the mothers in perinatal periods, and 
19% lower occurrence of anxiety disorders, compared to during the permuted 
periods. The fathers displayed similar although larger decreases, indicating 
that there indeed is a reduction in healthcare utilization during the perinatal 
periods, among both mothers and fathers alike. See Table 5.8. 
We observed a similar pattern among the mothers when the perinatal 
periods in the Stockholm County cohort were permuted, but a less 
pronounced decrease among the fathers as opposed to using the nation-wide 
cohort. The Stockholm County sub-sample covered only six years, 2004-
2009, consequently allowing less spread of the perinatal periods between 
individuals born the same year. Therefore the number of overlapping periods 
increased to 50%, and the time separating the permuted periods and the 
actual perinatal periods were reduced from around six years in the nation-
wide cohort, to around two years in the Stockholm County cohort. It is 
possible these differences between the two cohorts may explain the difference 
in estimates among the fathers when using the nation-wide data compared to 
when using the Stockholm County data. 
In additional analyses, the occurrence of healthcare utilization for any type of 
psychiatric condition was investigated between permuted and perinatal 
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periods and resulted in similar patterns of reduced healthcare utilization 
during the perinatal period. 
Overall, we observed reduced healthcare utilization for mental health 
problems in general during the perinatal period in both parents. However, 
this descriptive study reports patterns of healthcare utilization, but cannot 
provide answers to the underlying causes of these observed patterns. 
Nevertheless, the reduction in healthcare utilization would have to be 
explained either by a reduction in the underlying disorders during this time 
of life, or by barriers to receiving a diagnosis. The former interpretation may 
be intuitive; pregnancy is a period in life where most individuals spend more 
time in medical facilities compared to other times of life and thus may be 
more likely to have a depression detected, consequently lending support to 
the view that fewer hospital visits likely denotes fewer sick patients. It may 
further feel intuitive in a biological or evolutionary perspective that this 
important period in life should be "protected" against depression and 
anxiety. However, there are several studies reporting barriers to proper 
healthcare for mental illness during this particular time of life,72,87-89,91-93 
despite the potentially increased proximity to healthcare, which in turn could 
be explained by increased focus on the child and somatic complications, or 
stigma surrounding mental illness among both the patients and clinicians.72 
Furthermore, it has been estimated that as many as 75% of women may 
experience the "baby blues" following childbirth,237 a state of irritability, 
mood lability, tearfulness, generalized anxiety, and sleep and appetite 
disturbance, which may obscure depressive illness; even if the prevalence of 
perinatal depression is as high as 15%, the vast majority do not get depressed, 
but many do experience baby blues, making it potentially difficult for 
healthcare workers to distinguish the two in the postnatal period. It may 
further be argued that the common reaction of baby blues indicates that this 
is a normal reaction from a biological and evolutionary perspective. 
Additionally, if the period is protected against mood disorders, the observed 
reduction in healthcare utilization among both parents indicate that it would 
not be caused by the mother specific physiological changes during pregnancy 
and childbirth. 
Moreover, an interpretation that the reduced healthcare utilization denotes a 
decrease in the underlying disorder is contradictory to the results of a large 
body of previous research that relies on screening instruments. Using the 
Edinburg Postnatal Depression Scale, previous research has estimated the 
prevalence of perinatal depression at 10-15%,58-60,230,235 which is a high figure 
and far from the figure of 2% based on healthcare data observed in this study. 
On one hand, it could be argued that the screening tools ascertain everyone 
equally and does not rely on individual specific healthcare access, thereby 
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providing a more reliable estimate. On the other hand, it can be argued that a 
screening tool based on 10 items does equal a clinical examination and could 
potentially overestimate the prevalence. 
But apart from the discrepancy in estimate size from the two methods, there 
is also a discrepancy in timing of symptoms. Several studies using the 
Edinburgh Postnatal Scale to assess depressive symptoms during both the 
pregnancy and the time after childbirth report markedly higher occurrence of 
depressive symptoms during the pregnancy,71,238,239 which is completely 
opposite to what we observe using healthcare data. This further complicates 
the interpretation that the reduced healthcare utilization denotes reduced 
mental health issues. If this were the case, also these studies comparing the 
occurrence at different time points would have to be wrong. On the other 
hand, our results from the Stockholm County cohort (see Table 5.9 B) show 
that it is predominantly primary care visits that are reduced during the 
perinatal period, which may suggest that the antenatal or maternal 
healthcare fail to detect depressive illness that is detected by the primary are. 
In the end, both the interpretation that screening instruments may 
overestimate the true prevalence, and the interpretation that healthcare fails 
to detect a subset of individuals during the perinatal period may be true. 
Elevated anxiety levels in anticipation of the childbirth and reduced mood 
following childbirth are likely natural reactions to the physiological and 
mental challenge that pregnancy and childbirth constitute, but may risk 
getting defined as pathological conditions by screening instruments. 
However, if these reactions are indeed common and non-pathological, but 
also easily miss-classified as depressive illness, it is not unlikely that 
individuals with depressive illness gets obscured by the large number of 
parents that display similar symptoms without developing a disorder, and are 
instead assumed to experience a state of "baby blues" and will quickly 
recover.  
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 CONCLUSIONS  6.
   81 
In Study I, we developed and applied a pharmacoepidemiological model 
that compared the risk of antidepressant induced mood elevation - or manic 
switch - among bipolar disorder patients, and did so within the same 
individual, thereby automatically adjusting for a number of factors that could 
otherwise not be controlled for. This includes genetics, individual specific 
disorder severity, and other life-events up until the study started. Using this 
model, we could show that there was an increased risk of antidepressant 
induced manic switch, but that this effect was confined to the bipolar 
disorder patients that were treated with an antidepressant monotherapy. In 
contrary, among patients that also had a mood stabilizer, we did not observe 
this effect. This is particularly interesting since patients with a mood 
stabilizer treatment in this observational setting also are patients with more 
mania overall - that is why they had been prescribed the mood stabilizing 
treatment. But even with a generally larger rate of mania, we did not observe 
an antidepressant-induced switch among these patients. This could indicate 
that mood stabilizers are effective against antidepressant induced mood 
elevation, a side effect that is associated with worsening of disorder 
symptoms. However, the observed number of individuals that experienced a 
manic switch in the monotherapy group was low, and even if the observed 
number is an underestimate, not all patients with bipolar disorder appear 
affected by a manic switch from antidepressant medication. This is important 
as adding another medication on top of the antidepressant may risk more 
side effects, which could create more suffering and potentially reduce the 
adherence to the medication. The possibility that antidepressant induced 
manic switch is limited to a certain subset of bipolar disorder patients offers 
an interesting future direction. Exploring this possibility may result in 
clinically relevant information that could aid in tailoring a treatment that 
better fits the patient and reduces the side effects. 
In Study II, we utilized both a classical twin model with a validated self-
rating instrument, and a sibling model using national healthcare data, to 
estimate the heritability of perinatal depression. We observed that the 
heritability of perinatal depression was higher than the corresponding figure 
for non-perinatal depression. We also observed a unique genetic component 
behind perinatal depression that was not observed in depression occurring at 
other times of life. This is important, as previous studies of the genetic 
underpinnings of depression have not found any associated loci. This has led 
researchers to believe that depression is a grouping of symptoms that may 
include several different subtypes. By separating depression depending on 
when during life it occurred, either during a perinatal period or at any other 
time of life, and analyzing the two different types of depression with a 
bivariate model, we demonstrated genetic differences. This in turn may 
indicate perinatal depression is a different type of depression. This has a 
  82 
number of important implications for future research. The increased 
heritability of perinatal depression may make this type of depression a good 
candidate for genome-wide association studies, as genes play a larger role in 
the etiology. Furthermore, due to a different genetic profile, this type of 
depression may further implicate a different response to antidepressant 
treatment. 
In Study III, we first used a Swedish population-based cohort consisting of 
392,029 children and observed associations between prenatal SSRI exposure 
and birth size outcomes. However, using a sub-sample of 1,007 children in 
within-family analyses, consequently adjusting for numerous unmeasured 
shared confounders, only the association between SSRI exposure and 
reduced gestational age was observed. This association may be due to a 
causal effect of the medication, but could potentially be due to confounding 
factors that a within-family analysis cannot adjust for. These findings could 
indicate that many of the numerous associations between antidepressant 
medication during pregnancy and adverse outcome in the offspring may be 
due to underlying confounding factors, such as genetics or environmental 
exposures, and not the medication per se. This is important, as depression 
during pregnancy is not uncommon, and antidepressants are a central 
treatment option. However, this study could only focus on a finite number of 
outcomes, and more research is warranted to disentangle if similar results 
will be observed when a genetically informed design is used.  Moreover, the 
study underlines the complex mechanisms behind medication exposures and 
outcomes in observational settings, and highlights potential problems with 
confounding both when using a within-family design and when not. 
In Study IV, we approached the patterns of treatment for mental illness 
around the time of pregnancy on a broad scale using information from 
healthcare services nation-wide and over several decades. We further added 
information from Stockholm County specifically, to assess all types of 
medical care over a more recent time period. By comparing periods adjacent 
to the pregnancy, we observed a sudden decrease in healthcare contacts for 
depression and anxiety disorders among mothers. However, the fact that the 
chance of getting a diagnosis statistically increases with time and potentially 
influence the findings from our comparisons of adjacent periods, we also 
applied a permutation approach. This approach randomly interchanged the 
perinatal periods between parents of the same gender and birth year. Doing 
so, we were able to assess the occurrence of healthcare contacts during an 
individual’s perinatal periods, and contrast them to the occurrence in the 
same individual during permuted periods that would represent a biologically 
possible distribution, yet cover a non-perinatal time of life. When we 
compared the occurrence between these periods, we observed a decrease 
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during the real perinatal periods, which further gave support to the observed 
reduction in healthcare utilization for mental health related problems during 
this period in life. This reduction could either denote an actual decrease in 
mental illness, reduced detection, or both. More studies, preferably closer to 
the clinics, are warranted to unravel the mechanisms behind the observed 
patterns in healthcare utilization. 
In conclusion, the studies within this thesis demonstrate that genetically 
informed designs are very useful in epidemiological research. The genetically 
informed pharmacoepidemiological approaches, through the within-
individual design in Study I, and through the within-family design in study 
III, may be viewed as a combination of a classic epidemiological approach 
and a randomized controlled trial. As such, it may provide important 
information that would not been possible to acquire in other ways, or may 
have been a lot more costly to acquire using other methods. Even with strict 
criteria for inclusion, Study I includes far more subjects than would have 
been economically and morally plausible with a randomized controlled trial. 
Therefore, this type of observational study of medication effects may serve as 
an important first step that could be followed up with randomized controlled 
trials.  
Moreover, through the application of these designs with large-scale register 
data, the studies of this thesis provide enhanced understanding of mental 
illness in general, and bipolar disorder and perinatal depression in particular. 
In doing so, the work will hopefully provide information that will assist in 
moving away from the current stigmatized view of mental illness. To further 
get an idea of the potential future direction of mental illness, it can be useful 
to contrast mental illness to the somatic disorder of cancer, just like in the 
introduction of this thesis. Only a couple of decades ago, cancers were also 
stigmatized disorders, in which lack of understanding of the underlying 
complex mechanisms gave rise to ideas that cancer was in fact the result of 
"bad attitude".240 This was not only wrong, but also induced a lot of stress 
and anxiety among the individuals suffering from cancer.241 Today we know a 
lot more about cancers, and even though there is still stigma surrounding 
cancer, it is not as prevalent as before. In much the same ways, the lack of 
understanding surrounding mental illness commonly cause the suffering 
individuals to be blamed for their illness or outcomes as direct results of the 
illness.  
Hopefully, the field of psychiatric research will move in the same direction as 
the field of cancer research, and with increased understanding of the complex 
mechanisms behind the disorders, better treatment and less stigma will 
follow. 
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